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ABSTRACT 
UNCOVERING BUNYAVIRUS-HOST INTERACTIONS 
Mary Jane Drake 
Paul Bates 
Bunyaviruses are a large family of enveloped RNA viruses that are distributed globally 
and include many important human and agricultural pathogens. Compared with other pathogenic 
viruses, bunyaviruses are relatively understudied. Currently, there are no licensed vaccines or 
antivirals to treat bunyavirus infections in the United States. To better understand bunyavirus 
interactions with their mammalian hosts in the hopes of uncovering novel therapeutic targets, we 
utilized a forward genetic screening approach in a human haploid cell line (HAP1). We performed 
insertional mutagenesis of the HAP1 cells with a retroviral gene-trap vector and subsequently 
challenged the cells with recombinant vesicular stomatitis viruses (rVSV) encoding heterologous 
glycoproteins from representative bunyaviruses, severe fever with thrombocytopenia syndrome 
virus (SFTSV) and Andes virus (ANDV). The use of rVSV-SFTSV and rVSV-ANDV allows us to 
specifically interrogate the early steps of bunyavirus entry, as replication of VSV is uniformly 
cytotoxic. Selection of cells resistant to rVSV-SFTSV or rVSV-ANDV and sequencing of 
mutagenic integrations sites identified genes important for virus entry. For SFTSV, the synthesis 
of the glycolipid glucosylceramide was found to play a role in the proper trafficking and/or fusion 
of incoming virus particles. Selection with rVSV-ANDV uncovered a profound dependence upon 
cholesterol synthesis and a requirement for cholesterol in membranes for efficient internalization 
and fusion. In addition to discovering novel aspects of bunyavirus biology, both of these cellular 
pathways have FDA approved pharmacological inhibitors and future studies aim to determine 
whether these factors can serve as targets for antiviral intervention.  
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CHAPTER 1	  
 
INTRODUCTION  
Part I – The Virus 
Section 1.1 – General Bunyavirus Background 
 The Bunyaviridae family of RNA viruses can trace its origins to the isolation of 
Bunyamwera in 1943 from an Aedes mosquito (1), and since has grown to over 350 
different virus members. The family was formally established in 1975, and today is 
comprised of five genera, including the Orthobunya-, Phlebo-, Nairo-, Hanta-, and 
Tospoviruses (2). Outbreaks of bunyavirus-induced disease can be retrospectively 
traced back to the early 1900s (3,4). Bunyaviruses can be found worldwide and include 
many important human pathogens, such as Rift Valley fever virus, Crimean-Congo 
hemorrhagic fever virus, LaCrosse virus, and Puumala virus. Disease symptoms may 
include hemorrhagic fever, encephalitis, cardiopulmonary edema, renal disease, and 
multi-organ failure. Humans are considered incidental hosts since human-to-human 
transmission is inefficient and incredibly rare (3,5,6). Most bunyaviruses are transmitted 
to humans by arthropod vectors (e.g. mosquitoes, sandflies, ticks), with the exception of 
hantaviruses, that are transmitted by aerosolized rodent excreta, and tospoviruses, 
which are strictly plant pathogens (3). In the United States, there are currently no 
licensed vaccines or antiviral therapies to prevent or treat bunyavirus infection.  
 Bunyaviruses are composed of a tri-partite negative-sense or ambi-sense RNA 
genome, which is encapsulated by a nucleocapsid protein (N), and enveloped by a host-
derived lipid bilayer also containing an RNA-dependent RNA polymerase (L) and 
studded with heterodimeric glycoproteins (GN-GC). Virions are spherical or pleomorphic 
and approximately 80 to 120nm in diameter (3,7-13). The viral glycoproteins are 
synthesized as a polyprotein precursor and cleaved by host proteases to form GN and 
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GC, which dimerize to form the functional envelope protein. The viral glycoproteins are 
necessary and sufficient for virus entry into host cells. Cryo-electron microscopy studies 
have revealed that the heterodimeric glycoproteins associate with each other to form 
higher order oligomeric structures, and that these structures differ amongst the 
bunyavirus genera. It has been reported that the glycoproteins of phleboviruses 
Uukuniemi virus and Rift Valley fever virus form a T-12 icosahedral lattice (9,11), the 
glycoproteins of the hantaviruses Tula virus and Hantaan virus form a tetrameric square-
shaped assembly (10,12), and the glycoproteins of the orthobunyavirus Bunyamwera a 
tripod morphology (13).   
Section 1.2 – Phlebovirus Classification, Distribution, and Pathogenesis 
 The Phlebovirus genus of bunyaviruses is composed of over 80 viruses, many of 
which are classified into ten antigenically distinct species (3,14,15). Phleboviruses can 
be subdivided into two groups, those that are transmitted by phlebotomine sand flies or 
mosquitoes and those that are transmitted by ticks (Fig 2-6A) (15,16). Many 
bunyaviruses encode non-structural proteins that are synthesized during replication and 
are thought to antagonize host innate immune responses and facilitate replication (17). 
Of note, the sandfly viruses encode two non-structural proteins on the S and M genome 
segments, NsS and NsM, respectively, while the tick-borne viruses only encode one, 
NsS (15,16).  
Notable phleboviruses species include Rift Valley fever virus (RVFV), Sandfly 
fever Naples virus (SFNV), Punta Toro virus (PTV), Uukuniemi virus (UUKV), and the 
recently characterized severe fever with thrombocytopenia syndrome virus (SFTSV). 
The best characterized of these are Rift Valley fever virus and Uukuniemi virus. 
However, with development of high throughput sequencing technologies, the number of 
phleboviruses is rapidly expanding as viruses are identified from environmental 
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reservoirs (18,19). The newest pathogenic members include two closely related viruses, 
SFTSV and Heartland virus (HRTV), which were found to cause disease in eastern Asia 
(China, Japan, South Korea) and the Midwestern United States, respectively (20-22).  
Over 3,500 cases of SFTSV have been reported in China since 2011, with an 
average case-fatality rate of 7.8% (23). Hospitalized patients presented clinically with 
fever and gastrointestinal symptoms while laboratory findings most commonly included 
thrombocytopenia, leukocytopenia, neutropenia, with elevated lactate dehydrogenase 
and liver enzymes, the latter indicating multi-organ failure (20,24,25). The overwhelming 
majority of patients were male farmers over the age of 50 years that lived in wooded or 
hilly areas (20,23,25). Epidemiological studies in endemic regions found seroconversion 
rates of 0.3-6.6% in humans (26-28) and 40-70% in livestock (29). Haemaphysalis 
longicornis ticks (Ixodidae family) have been found to harbor SFTSV viral RNA that is 
highly similar (>93%) to that isolated from humans (20,30,31), indicating that ticks are 
likely the transmitting vector. The first reported cases of SFTSV were found in patients 
from the Henan and Hubei provinces in China (20), however since then SFTSV has 
been reported in 20 provinces in China as well as Japan and South Korea (23,32,33), 
indicating a wide geographical distribution.   
Heartland virus was first discovered in 2009 from two individuals hospitalized 
with severe febrile illness in Missouri (22). More recently, seven additional cases have 
been identified In Missouri and Tennessee (34), although none have been directly 
responsible for patient fatality. Clinical symptoms were similar to SFTSV in that they 
included fever and gastrointestinal abnormalities, while laboratory findings included 
leukopenia, thrombocytopenia, and elevated hepatic aminotransferase levels (22).  
Epidemiological studies have found HRTV RNA in Amblyomma americanum ticks (Lone 
Star Tick, Ixodidae family) collected in Missouri (35) as well as serum antibodies in deer, 
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raccoons, and coyotes throughout the central and eastern United States (36). While 
HRTV and SFTSV have both been detected in hard shell ticks belonging to the Ixodidae 
family, neither has been found in mosquitoes, heavily suggesting transmission via tick 
bite. Furthermore, phylogenetic analysis of the phlebovirus genus clusters these novel 
viruses amongst the tick-borne species (Fig 2-6A)(15).  
Section 1.3 – Hantavirus Classification, Distribution, and Pathogenesis 
 Members of the Hantavirus genus are unique within the Bunyaviridae in that their 
transmission to humans occurs via inhalation of aerosolized rodent excreta, rather than 
arthropod bite. They can be classified into two groups, Old World and New World 
hantaviruses, which is based on their geographical distribution in Eurasia and the 
Americas, respectively (37). The two groups also cause distinct pathologies, with the Old 
World hantaviruses causing hemorrhagic fever with renal syndrome (HFRS) and the 
New World hantaviruses inducing hantavirus cardiopulmonary syndrome (HPS) (37-39).  
 Hallmarks of HFRS include fever, thrombocytopenia, and acute renal failure. 
Typically around the eighth day of disease onset, hemorrhagic symptoms become more 
pronounced due to increased vascular capillary permeability and vascular leakage (40). 
Mortality associated with HFRS causing viruses is 0-15% (37). In contrast, HPS is 
associated with a much higher fatality rate of 40-50% (37). Hantavirus cardiopulmonary 
syndrome is marked by fever, interstitial pulmonary edema with acute respiratory failure 
and cardiac dysfunction. Pulmonary edema is thought to occur from increased capillary 
permeability in the lung vascular endothelium (40,41).  
 Notable Old World pathogenic hantaviruses include Hantaan virus (HTNV), Seoul 
virus (SEOV), Puumala virus (PUUV), and Dobrava virus (DOBV), while Andes virus 
(ANDV) and Sin Nombre virus (SNV) are important pathogenic New World hantaviruses. 
Within their rodent reservoirs, hantaviruses do not cause disease (3), which is thought to 
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be due to millions of years of co-evolution (37,42,43). Hantaviruses are highly restricted 
to their rodent reservoirs, to the extent that a given hantavirus is typically found in a 
single rodent species (43). Phylogenetic analysis of hantaviruses reveals a segregation 
based on disease pathology as well as by the rodent family that serves as their 
reservoir. For example Old World hantaviruses are found in rodents belonging to the 
Muridae family, while New World hantaviruses are found in rodents of the family 
Cricetidae (42). 
Part II – The Host 
Section 1.4 – Entry mechanisms of viruses 
 The first step in virus replication is the binding and entry into a permissive host 
cell. The entry process can be described by discrete stages (Fig 1-1), beginning with the 
binding of a virion to a cell. Virus attachment is typically mediated by protein-protein or 
protein-carbohydrate interactions. These interactions can be high affinity or high avidity 
depending on the number of viral envelope glycoproteins and/or abundance of cellular 
receptors or attachment factors. Following attachment at the cell surface, viruses either 
fuse at the cell surface following receptor engagement, or require endocytosis before 
fusion within an intracellular compartment. For endocytosis-dependent viruses, 
internalized virions traffic through the endo-lysosomal network in order to undergo a pH-
dependent conformational change or encounter intracellular proteases that are required 
for priming fusion machinery (44,45). While fusion of pH-dependent viruses typically 
occurs within an endosome or lysosome, other viruses have been shown to exit the 
endo-lysomal network and traffic to the ER or Golgi complex (46-49). Additionally, a pH-
induced conformational change is sufficient for many endocytosis-dependent viruses to 
undergo virus-host membrane fusion, however some viruses require engagement with 
an intracellular receptor (50-52).  
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 Endocytosis can be mediated by several processes, although viruses are 
typically thought to utilize a particular process within a given cell type. Clathrin-mediated 
endocytosis (CME) is the best-characterized endocytic pathway and a common uptake 
mechanism co-opted by viruses. CME involves the formation of a clathrin lattice that 
comprises clathrin-coated pits (CCP), which in turn induces membrane curvature. 
Adaptor proteins such as AP2 and eps15, as well as the actin cytoskeleton are thought 
to be involved in the formation of clathrin-coated vesicles. Dynamin-2 pinches off newly 
formed vesicles from the plasma membrane, where they can then traffic towards the 
nucleus (53-55). Caveolin-mediated endocytosis (CavME) resembles CME in that it 
involves a coat protein for vesicle formation, however the formation of caveolar vesicles 
requires cholesterol and occurs in lipid rafts. Many viruses that utilize caveolar-
dependent endocytosis have glycosphingolipid receptors (53). Similarly to CME, 
dynamin-2 is also required for vesicle scission during CavME. Other non-clathrin, non-
caveolin-dependent entry pathways exist. Macropinosytosis is a dynamin-independent 
process that involves ruffling or blebbing of the plasma membrane with concomitant 
fluid-phase and particle uptake in large, uncoated vesicles. Actin, tyrosine kinases, PI3K, 
and many GTPases are required in this process (53). Macropinocytosis may be 
important for viruses that are too large to be enclosed in CME or CavME vesicles. 
Additional clathrin- and caveolin-independent endocytic processes do exist, although 
comparatively they are poorly understood. 
Section 1.5 – Bunyavirus entry 
 Bunyavirus entry into permissive cells is mediated by the viral glycoproteins GN 
and GC. The transmembrane proteins form a heterodimer on the virion surface and are 
involved in attachment and receptor engagement. Attachment factors for bunyaviruses 
have not been fully characterized, although some important factors for phleboviruses 
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and hantaviruses are discussed below. Importantly, no universal receptor has been 
identified for the virus family, or within a given genus.  
 Similar to other enveloped viruses, bunyaviruses require endocytosis for entry. A 
number of bunyaviruses from diverse genera have been reported to use clathrin-
mediated endocytosis, including LaCrosse, Oropuche, Hantaan, and Crimean-Congo 
hemorrhagic fever viruses (56-60). However, clathrin-independent mechanisms such as 
caveolin-mediated endocytosis and macropinocytosis have also been described for 
other bunyaviruses (61-64). All bunyaviruses examined to date require endosomal 
acidification for productive entry. The low pH environment triggers conformation changes 
in the glycoprotein that are thought to promote fusion of virus and host membranes. 
Exposure to low pH prior to infection neutralizes virus infection (65), and pre-treatment of 
cells with lysosomotropic agents such as ammonium chloride (NH4Cl) or bafilomycin A 
blocks infection of bunyaviruses (60,63,65-67). Moreover, infection can occur by 
triggering fusion of bound virions at the cell surface using a pulse of low pH buffer 
followed by neutralization and addition of NH4Cl (63,67). Endocytic trafficking of 
incoming bunyavirus particles is much less characterized, but viruses have been 
reported to enter the endo-lysosomal network, with fusion occurring in early endosomes 
(56), multi-vesicular bodies (68), and even in late endosomes or lysosomes (63), 
depending on the virus species.  
Section 1.6 – Phlebovirus entry 
 Several cellular molecules have been reported to facilitate phlebovirus 
attachment and endocytosis into mammalian cells. The phleboviruses UUKV, RVFV, 
and SFTSV have been shown to utilize the C-type lectin DC-SIGN for attachment (69-
72). Studies carried out in cell lines weakly permissive to phlebovirus infection (Raji, 
HeLa) found that overexpression of DC-SIGN significantly enhanced virus infection, 
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which could be specifically blocked by addition of mannan or anti-DC-SIGN antibodies. 
The molecule DC-SIGN-related (DC-SIGNR) was also shown to enhance SFTSV 
infection (71), while L-SIGN, normally expressed on liver sinusoidal endothelial cells, 
was reported to enhance attachment of UUKV but was not sufficient to promote 
endocytosis (73). Given DC-SIGN’s affinity for high mannose sugars and that 
phleboviruses contain several putative N-linked glycosylation sites, it is unsurprising that 
DC-SIGN overexpression can enhance infection. However, given the limited 
endogenous expression of DC-SIGN to dendritic cells and the wide tropism of 
phleboviruses in cell culture, other molecules are also likely to play a role in attachment 
and endocytosis of virions. 
 Other factors have also been identified for promoting phlebovirus attachment and 
entry. Two independent studies identified a role for the proteoglycan heparan sulfate in 
RVFV attachment to host cells (74,75). Heparan sulfate is one of many cellular 
glycosaminoglycans (GAGs) that forms linear polysaccharides on the surface of cells 
and is important for interacting with extracellular proteins as well as regulating diverse 
biological processes (76).  Studies by de Boer et al found that Chinese hamster ovary 
(CHO) cell mutants lacking enzymes critical to GAG biosynthesis greatly reduced RVFV 
infection compared to wild-type cells (74). Additionally, pre-treatment of virus with 
heparin or enzymatic removal of heparan sulfate blocked RVFV infection. Heparan 
sulfate biosynthesis was also identified using a haploid forward genetic screen 
(described in detail below) with the attenuated RVFV strain MP-12 (75). Those studies 
established that heparan sulfate was critical for binding of RVFV to cells, and that clinical 
isolates of RVFV that have not been passaged extensively in tissue culture were also 
affected by impaired heparan sulfate synthesis, indicating that heparan sulfate may also 
be important in vivo (75). 
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 One report has described a specific attachment factor for SFTSV. Using a tagged 
SFTSV GN, Sun et al, performed immunoprecipiation experiments with Vero cell lysates 
followed by mass spectrometry (77). LC-MS/MS identified an interaction between 
SFTSV GN and non-muscle myosin heavy chain-IIA (NMMHC-IIA). Knockdown of 
NMMHC-IIA reduced infection with SFTSV, while overexpression in weakly permissive 
HeLa cells greatly enhanced infection. The authors found that NMMHC-IIA re-localized 
to the cell surface upon virus infection and that pre-treatment with a myosin light chain 
inhibitor reduced the amount of cell-associated virus 15 minutes post-warming in 
immunofluorescence microscopy experiments, indicating an entry defect (77). However, 
further studies will be needed to determine whether NMMHC-IIA is directly interacting 
with SFTSV at the cell surface, or that the motor protein function of NMMHC-IIA is 
important for internalization of virions, as it is difficult to envision how the normally 
cytosolic NMMHC-IIA interacts with an extracellular virion.  
 Following attachment, phleboviruses undergo endocytosis and various 
mechanisms have been reported to facilitate this process. Electron microscopy studies 
by Lozach et al observed UUKV in mostly uncoated pits during endocytosis, although 
virions were seen to localize to clathrin-coated pits in some rare cases (63). Additionally, 
siRNAs targeting clathrin light chain had no effect on UUKV infection (63). For RVFV, 
three separate studies have each identified a unique endocytic uptake mechanism for 
the virus, including CME (67), caveolin-mediated endocytosis (64), and 
macropinocytosis (62). The observed differences in uptake mechanisms utilized by 
RVFV may be due to the different cell types or virus strains used in each of the studies. 
Lastly, entry studies using SFTSV glycoprotein pseudotyped onto a vesicular stomatitis 
virus (VSV) core have found that SFTSV entry is dynamin-dependent and PI3K 
independent, suggesting a clathrin- or caveolin-mediated process, although some 
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clathrin- and caveolin-independent processes have been shown to also require dynamin 
(53,71,78).   
 The final stages of phlebovirus entry involve intracellular trafficking to a low pH 
compartment where virus fusion occurs. UUKV has been described to traffic within 
Rab5- and Rab7-positive endosomes as well as LAMP-1-positive endo-lysosomes, 
suggesting that it is a late-penetrating virus (63). Acid bypass studies also indicated that 
a pH of 5.5 or below was required for efficient UUKV infection from the plasma 
membrane (63). The pH of early endosomes ranges from 6.0-6.5 while late endosomes 
and lysosomes reach a pH of 5.0-5.5 (53). Furthermore, studies with RVFV have also 
indicated that it is a late-penetrating virus, as acid-bypass experiments require a pH of 
5.5 or below to restore infectivity and pre-incubation of virus at pH 5.0-5.5 reduced 
infection by >50% (67). The results described in Chapter 2 are the first report on the 
intracellular trafficking of SFTSV. 
Section 1.7 – Hantavirus entry 
 Hantavirus attachment to cells has been shown to be mediated by integrins, 
specifically β3 and β1 integrins (79-82). Integrins composed of α and β subunits form 
heterodimeric receptors on the cell surface and are important for mediating cell-cell 
adhesion, platelet aggregation, and interacting with the extracellular matrix (83,84). 
Studies by Gavrilovskaya et al have found that αVβ3 integrins are important for mediating 
entry of pathogenic hantaviruses such as Andes virus (ANDV), Sin Nombre virus (SNV), 
Hantaan virus (HTNV), Seoul virus (SEOV), and Puumala virus (PUUV) while α5β1 is 
required for non-pathogenic hantaviruses Prospect Hill (PHV) and Tula viruses (TULV) 
(79,80). The difference in integrin usage may contribute to the pathogenicity of certain 
viruses, although the pathologies of HFRS and HPS are quite different. Interestingly, β3 
does play a role in maintaining vascular integrity and regulating the endothelial cell 
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barrier, although a direct link between hantavirus infection, β3 attachment, and vascular 
permeability has yet to be established in vivo. Furthermore, studies by other groups 
have found that αVβ3 integrin surface expression does not correlate with cell infectivity of 
PUUV or HTNV pseudotypes, suggesting other factors may be involved (65,66).  
 In addition to integrins, decay-accelerating factor (DAF) has also been shown to 
play a role in hantavirus attachment and entry (85). Using polarized endothelial cells, 
Krautkramer et al showed that HTNV and PUUV enter from the apical surface and that 
pre-treatment of cells with anti-DAF antibodies or virus with soluble, recombinant DAF 
blocked infection (85). Intriguingly, αVβ3 is expressed on the basolateral surface of 
polarized endothelial cells, and so the authors propose a DAF-mediated translocation 
event to tight junctions may be required for αVβ3 interactions, similar to the role of DAF in 
coxsackievirus entry (85,86).  
 Internalization of hantaviruses has been primarily shown to require clathrin-
mediated endocytosis (58,61). However, ANDV has been reported to use other non-
CME, non-CavME pathways (61). Additionally, acid neutralization studies of PUUV and 
HTNV pseudotypes (VSV core) found that virus pre-incubation at pH 6.0 and below 
effectively neutralized the virus, indicating that these viruses may fuse in the early 
endosome or multivesicular bodies (65). However, no careful studies looking at the 
trafficking of internalized hantavirus particles have been reported.  
Part III – Mechanisms for Studying Viral Entry with Haploid Genetics 
Section 1.8 – Identification of a human haploid cell line (HAP1) 
 Forward genetic screens involving mutagenesis of haploid cells or organisms 
have been extensively used to map the genetic requirements for various biological 
processes. Until the isolation of clonally derived human haploid cells, yeast and 
prokaryotes were the major model systems for screening. In 1999, Kotecki et al 
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described the isolation of a near-haploid clone from non-adherent KBM-7 cells, a 
heterogeneous chronic myeloid leukemia (CML) cell line isolated from a human patient 
(87). The cells were haploid with the exception a disomy of chromosome 8. 
Approximately a decade later, Jan Carette and Thijn Brummelkamp et al reported the 
first use of the near-haploid KBM-7 clone in a retrovirus-induced mutagenesis screen 
(88). This was the first report of a haploid genetic screen in human cells. In the report, 
the authors challenged the mutagenized cells with various toxins, chemotherapeutic 
drugs, as well as influenza virus, and sequenced integration sites within surviving cells 
by serial dilution and Sanger sequencing (88). Sequencing identified retroviral 
integration sites in genes previously identified to be required for the intoxication or 
infection of cells, establishing proof of principle for this screening technology (88). 
Advancements in the screening process utilized high throughput sequencing and 
statistical enrichment analysis to compare integration site distribution frequencies in 
selected and unselected control populations, greatly increasing the depth and 
robustness of the screening technology (89). 
 In subsequent studies, Carette et al attempted to reprogram the KBM-7 cells into 
pluripotent stem cells by transduction with the Yamanaka factors (KLF4, SOX2, c-MYC, 
OCT4), which resulted in the generation of an adherent, fully haploid clone which they 
named HAP1 (50). The generation of HAP1 cells was a major breakthrough in haploid 
genetic screening since many viruses require the expression of cellular adhesion factors 
for entry, increasing the utility of the screening approach for studies of viral infection. 
Furthermore, monosomy of chromosome 8 allowed for interrogation of genes on that 
chromosome that may otherwise be overlooked due to redundancy. These HAP1 cells 
are the basis for all reported subsequent haploid genetic screens.  
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Section 1.9 – Overview of HAP1 screening 
 Haploid genetic screens (Fig 2-1A) utilize a retroviral insertional mutagenesis 
strategy in HAP1 cells in order to create a library of genetic knockouts. Screens 
completed by the Brummelkamp and Carette labs have used a murine leukemia virus 
(MLV)-based gene trap, while investigations in our lab have employed a lentiviral-based 
vector due to the preference for lentiviruses to integrate within genes, rather than near 
transcription start sites, as is the case with MLV (88,90). In both cases, the gene traps 
encode strong splice acceptor and splice donor signals to incorporate GFP and/or 
antibiotic resistant cassettes into endogenous genes, effectively disrupting normal gene 
function (91)(Fig 3-1A). A subset of the mutagenized library then undergoes negative 
selection by the addition a cytotoxic agent of interest (e.g. virus, bacterial toxin, 
chemotherapeutic agent). The cells surviving challenge are allowed to expand briefly 
before being pooled and their genomic DNA is isolated and prepped for targeted deep 
sequencing of retroviral integration sites (92). Integration sites mapped in the selected 
population are then compared to the distribution of integration sites in an unselected 
control population. A Chi-Square test with false-discovery rate correction is used to 
identify genes with a significantly greater number of independent integrations than 
expected based on the control library. These genes are considered “enriched” in the 
selected population and form a candidate list of genes for follow-up studies.    
Section 1.10 – Successful applications of HAP1 screens to identify cellular 
requirements for virus entry 
 Key advancements in the understanding of virus-host interactions have been 
made using haploid forward genetic screens, most notably in determining virus entry 
requirements. HAP1 screens have identified virus receptors and key regulators of 
endocytic trafficking. Several HAP1 screens have utilized recombinant vesicular 
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stomatitis viruses (rVSV) encoding orthogonal viral glycoproteins in place of VSV G to 
specifically define virus entry requirements for a virus of interest. This is particularly 
useful for studying the entry processes of highly pathogenic viruses that would otherwise 
be cost-prohibitive or intractable for cell culture.  
The first major virus HAP1 screen involved the use of an rVSV encoding the 
glycoprotein of Ebola virus Zaire (rVSV-EBOV) (50). The screen discovered the 
cholesterol transporter Niemann-Pick C1 (NPC1) as an intracellular receptor for Ebola 
virus (EBOV). Infection of NPC1-mutant cells with authentic EBOV was also greatly 
reduced compared to normal cells (50). Additionally, NPC1 knockout mice were highly 
resistant to infection with EBOV, indicating that NPC1 is required in the context of bona 
fide EBOV infection (50). The screen also found a significant enrichment of integrations 
in cathepsin B (CatB) and members of the HOPS complex, a pH-dependent cysteine 
protease and tethering complex required for lysosome maturation, respectively. CatB 
was previously established to be required for proteolytic cleavage of the EBOV 
glycoprotein during the entry process (44,93) and the only hit in the screen previously 
shown to be important for EBOV entry. rVSV-EBOV infection was also greatly inhibited 
in cells lacking individual members of the HOPS complex. Electron microscopy revealed 
the accumulation of virus particles within a vesicular compartment, indicating lysosomal 
maturation was needed for virus fusion and escape (50). In unpublished work from our 
lab, we also screened our own HAP1 library with rVSV-EBOV and similarly identified 
various members of the HOPS complex and NPC1, indicating that this screening 
approach is highly reproducible and further confirming a role for these factors in EBOV 
entry.  
Other notable HAP1 screens completed by Thijn Brummelkamp’s group include 
the use of an rVSV encoding the glycoprotein of Lassa virus (rVSV-LASV) (51,94), a 
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hemorrhagic fever-inducing arenavirus that had been previously shown to require α-
dystroglycan (α-DG) for attachment and as a putative receptor (95). The first HAP1 
screen with rVSV-LASV confirmed α-DG synthesis as critical for LASV entry, but also 
revealed several enzymes involved in α-DG biosynthesis that were previously unknown 
(94). Interestingly, the authors found mutations in the newly characterized genes in 
patients with dystroglycanopathies, who lacked mutations in known disease-causing 
genes, expanding the testable genes for these hereditary diseases. A follow-up study by 
Jae et al found that glycosylated LAMP1 functions as an intracellular receptor for LASV 
entry (51). At neutral pH, LASV glycoprotein (GP) bound strongly to α-DG, whereas at 
acidic pH, GP had reduced affinity for α-DG and strong affinity for LAMP1. This 
interaction was dependent upon a single N-linked glycosylation site. Mice lacking 
LAMP1 were highly resistant to LASV infection (51). Together, this screen, along with 
the rVSV-EBOV studies, has identified unappreciated intracellular receptors for viruses. 
As highlighted previously with rVSV-EBOV, HAP1 screens are highly 
reproducible. Another example of this is two independent HAP1 screens performed with 
an rVSV encoding the glycoproteins of the hantavirus Andes virus (rVSV-ANDV) (96,97). 
Our lab identified the cellular cholesterol regulatory pathway as critical for ANDV entry 
(discussed in Chapter 3) and this finding was confirmed independently by Kartik 
Chandran’s group (97). The cholesterol regulatory pathway, comprised of sterol 
regulatory element binding protein 2 (SREBP2), SREBP cleavage activating protein 
(SCAP), site-1-protease (S1P) and site-2-protease (S2P), forms a regulated switch to 
induce cholesterol synthesis and scavenging under conditions of cholesterol depletion. 
Cellular entry of Andes virus, as well as the hantaviruses Puumala, Sin Nombre, and 
Hantaan, was inhibited in cells treated with a S1P inhibitor that caused decreased 
cellular cholesterol levels (96,97). We established that cholesterol is required for efficient 
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internalization, while Kleinfelter et al went on to show that the kinetics of internalization 
are slowed in cholesterol-depleted cells but internalization levels can eventually catch up 
to those in cholesterol replete cells at later time points (>60 minutes) (96,97). We and 
Kleintfelter et al have also shown that cholesterol is required in the target membrane for 
hantavirus fusion, such that replenishing cholesterol in target membranes of S1P 
inhibitor-treated cells can restore infection with Andes virus and Puumala virus (97 and 
Dyer, Drake et al. in preparation). Together, these studies have identified a highly 
sensitive dependency of hantaviruses on cholesterol during the entry process.  
 In addition to screens utilizing rVSVs, authentic virus screens have been 
performed, including one with the phlebovirus Rift Valley fever virus (RVFV). The HAP1 
screen used the attenuated strain MP-12 and found a profound dependence on heparan 
sulfate biosynthesis (75), confirming a previous report identifying a role for heparan 
sulfate in RVFV infection (74). Heparan sulfate proteoglycans form a critical component 
of the extracellular matrix and being highly negatively charged, are thought to facilitate 
virus attachment via electrostatic interactions (98). Blocking of heparan sulfate with the 
small molecule surfen greatly reduced RVFV infection (75). Mechanistically, inhibition of 
heparan sulfate biosynthesis led to decreased binding of RVFV particles to cells as 
compared to wild-type cells, likely accounting for decreased infection levels (75). 
Additionally, the screen identified PTAR1 as a novel regulator of heparan sulfate 
biosynthesis, as PTAR1 deletion resulted in decreased surface expression of heparan 
sulfate, subsequently leading to a decrease in RVFV infection (75).  
 Lastly, our lab performed a HAP1 screen utilizing an rVSV encoding the 
glycoproteins of the phlebovirus severe fever with thrombocytopenia syndrome virus 
(rVSV-SFTSV). The screen identified UDP-glucose ceramide glucosyltransferase 
(UGCG), the enzyme responsible for initiation of de novo glycosphingolipid biosynthesis, 
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as critical for efficient rVSV-SFTSV infection. Infections with authentic SFTSV confirmed 
a role for UGCG during natural infection, while mechanistic studies found that UGCG 
inhibition leads to the aberrant accumulation of virus particles during entry. The details of 
this study will be discussed in Chapter 2.  
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Fig 1-1: Overview of bunyavirus entry. Bunyavirus entry can be generally described 
by virus attachment at the cell surface, receptor-mediated endocytosis, and trafficking to 
the early or late endosome where virus fusion occurs in a pH-dependent manner (3,99). 
The pH of early endosomes is typically 6.0-6.5, late endosomes a pH of 5.0-6.0, while 
endo-lysosomes and lysosomes have a pH of 4.5-5.0 (53). Fusion results in release of 
the viral ribonucleoproteins (vRNP) into cytoplasm and initiation of replication. Image 
was created by Hannah Barbian for this publication. 
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CHAPTER 2 
 
A ROLE FOR GLYCOLIPID BIOSYNTHESIS IN SEVERE FEVER WITH 
THROMBOCYTOPENIA SYNDROME VIRUS ENTRY 
 
Reprinted with minor changes from the submitted manuscript: 
Drake MJ, Brennan B, Briley KE, Sherman E, Szemiel AM, Minutillo M, Bushman FD, 
Bates P (2016) A Role for Glycolipid Biosynthesis in Severe Fever with 
Thrombocytopenia Syndrome Virus Entry. 
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Section 2.1 – Abstract 
A novel bunyavirus was recently found to cause severe febrile illness with high 
mortality in agricultural regions of China, Japan, and South Korea. This virus, named 
severe fever with thrombocytopenia syndrome virus (SFTSV), represents a new group 
within the Phlebovirus genus of the Bunyaviridae. Little is known about the viral entry 
requirements beyond showing dependence on dynamin and endosomal acidification. A 
haploid forward genetic screen was performed to identify host cell requirements for 
SFTSV entry. The screen identified dependence on glucosylceramide synthase (ugcg), 
the enzyme responsible for initiating de novo glycosphingolipid biosynthesis. Genetic 
and pharmacological approaches confirmed that UGCG expression and enzymatic 
activity were required for efficient SFTSV entry. Furthermore, inhibition of UGCG 
affected a post-internalization stage of SFTSV entry. Internalized virions were observed 
trafficking to EEA1+ early endosomes, and co-localizing with the trans-Golgi marker 
TGN46 at later time points. Minimal co-staining with the endo-lysosomal markers Rab7 
and LAMP-1 suggested that SFTSV might utilize an entry pathway distinct from other 
phleboviruses. Inhibition of UGCG enzymatic activity led to the accumulation of virus 
particles in enlarged cytoplasmic structures, suggesting impaired trafficking and/or fusion 
of viral and host membranes. These findings specify a role for glucosylceramide in 
SFTSV entry and provide a novel target for antiviral therapies. 
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Section 2.2 – Introduction 
Emerging viruses pose a public health threat that is increasing with rapid global 
transit and continued urbanization. Technological advancements have made it easier to 
identify new viral threats and disseminate information to the public. However, the 
development of antiviral therapies and vaccines to these new threats remains slow. In 
2011, a novel virus was reported causing severe fever and thrombocytopenia in China, 
with a ~10% mortality rate among hospitalized patients (1-3). The virus, named severe 
fever with thrombocytopenia syndrome virus (SFTSV), was found to be a novel 
bunyavirus belonging to the Phlebovirus genus. Other notable members include Rift 
Valley fever virus (RVFV) and Uukuniemi virus (UUKV) (4,5). Similar to other 
phleboviruses, SFTSV is transmitted by biting insects, specifically Ixodidae ticks, which 
were found to carry viruses highly similar (>93%) to those from human isolates (6). Since 
2011, epidemiological studies have found 0.8-3.6% of people are seropositive for 
SFTSV in endemic regions and seroconversion rates of 45-70% in livestock (7-9) 
revealing a much wider distribution than previously thought. Further study showed that 
the geographic distribution of SFTSV extended into South Korea and Japan (10-12).  
Since its discovery, SFTSV has come to be better understood clinically (13,14), but 
many fundamental aspects of the virus biology remain to be elucidated.  
 The Bunyaviridae family of negative-sense RNA viruses is large and diverse with 
5 genera and over 300 species identified to date (15). The tripartite genome is 
comprised of the S, M, and L segments, which encode the nucleocapsid, glycoproteins, 
and RNA-dependent RNA polymerase, respectively. In addition to the structural proteins, 
some bunyaviruses, including SFTSV, also encode non-structural proteins that 
antagonize host innate immune mechanisms (16-19). The viral glycoproteins GN and GC 
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form a heterodimer on the surface of virions, and are both necessary and sufficient for 
viral entry (15). 
Studies on the entry of bunyaviruses have identified a requirement for 
endocytosis and acidification of endosomes for productive virus infection (15). SFTSV 
has been shown similarly to require a dynamin-dependent, endocytic process and 
endosomal acidification for efficient entry (20,21). Additionally, the C-type lectin DC-
SIGN has been reported to be a receptor for phleboviruses in dendritic cells (UUKV, 
RVFV) (22,23), and Raji cells overexpressing DC-SIGN or DC-SIGN-related protein 
have enhanced susceptibility to SFTSV-glycoprotein mediated infection (20,21). 
However, given the limited expression of DC-SIGN and the contrasting wide tropism of 
SFTSV, additional host factors are likely involved in receptor-mediated endocytosis of 
SFTSV. 
Phylogenetic analysis of the phlebovirus genus has revealed that SFTSV shares 
only 30-35% glycoprotein amino acid similarity with RVFV and UUKV (1) (Fig 2-6A), and 
represents a new group within the genus. Based on this difference, SFTSV may have 
unique requirements for entry into mammalian cells.  
In order to identify host factors required for the efficient entry of SFTSV, we 
performed a forward genetic screen in a human haploid cell line (HAP1) (24-27). 
Previous HAP1 screens have been successful at elucidating key requirements of virus 
entry, including the Ebola virus receptor NPC1 (26), the need for cholesterol in 
hantavirus membrane fusion (27,28), and more recently, the identification of the Adeno-
Associated Virus receptor AAVR (29). The present HAP1 screen identified 
glucosylceramide synthase (ugcg, referred to as UGCG) as being essential for the 
efficient entry of SFTSV. UGCG is a Golgi-resident transmembrane protein that 
functions as the initiation step of glycosphingolipid (GSL) biosynthesis and is required for 
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the synthesis of gangliosides, globosides, and other cellular GSL species. Using genetic 
and pharmacological approaches, UGCG expression and enzymatic activity was 
confirmed to be required for efficient SFTSV entry. Mechanistic studies identified a role 
for UGCG in the proper trafficking of incoming virions, as cells treated with UGCG 
inhibitors caused virus particles to accumulate in large cytoplasmic structures. Together, 
these studies are the first to use an unbiased genetic screen to discover host factors 
required for SFTSV entry and provide a possible target for therapeutic intervention. 	  
 
Section 2.3 – Results 
Haploid forward genetic screen for SFTSV entry factors identifies candidate genes 
To identify host factors that are required for entry of SFTSV, we performed a 
forward genetic screen in HAP1 cells, a human haploid cell line (26) (Fig 2-1A). HAP1 
cells were mutagenized with a lentiviral gene-trap vector to create a library of genetic 
knockouts by insertional mutagenesis. Viral challenge of these cells creates a genetic 
bottleneck, whereby cells harboring mutations in pro-viral genes undergo positive 
selection. Comparison of mutations in the virus-challenged population to an unselected 
control population allows for assessment of differences in mutational frequency across 
the genome. Approximately 75 million mutagenized HAP1 cells were infected with a 
recombinant vesicular stomatitis virus (VSV) encoding the glycoprotein of SFTSV (strain 
HB29, rVSV-SFTSV) in place of VSV G. Challenge of non-mutagenized HAP1 cells with 
rVSV-SFTSV or mutagenized HAP1 cells with wild-type VSV left no surviving cells 7-10 
days post infection. In contrast, mutagenized HAP1 cells challenged with rVSV-SFTSV 
resulted in several hundred surviving colonies, suggesting that survival was due to 
mutations in genes essential for SFTSV glycoprotein-mediated entry. Following  
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Fig 2-1: Haploid 
genetic screen 
identifies SFTSV 
entry factors (A) 
Overview of haploid 
genetic screen. 
Briefly, HAP1 cells 
were mutagenized 
using a lentiviral 
insertional 
inactivation strategy 
to create the HAP1 
library. Cells were 
then infected with 
the cytotoxic rVSV-
SFTSV (MOI 1) and 
after two weeks 
surviving colonies 
were collected for 
integration site 
analysis. Lentiviral 
integration sites in 
the surviving 
population as well 
as in the unselected 
control population 
were sequenced 
and mapped to the 
human genome. 
Enrichment analysis 
using a chi-square 
exact test and correcting for false discovery was employed to identify genes 
overrepresented in the selected population. (B) Parental (non-mutagenized) HAP1 cells 
and mutagenized HAP1 cells surviving rVSV-SFTSV selection (HAP1-SFTSVR) were 
subject to a single-cycle infection (8-10hr) with a panel of recombinant vesicular 
stomatitis viruses (rVSVs) encoding various viral glycoproteins. Infection in HAP1-
SFTSVR cells is normalized to infection in the parental HAP1 cells. SFTSV = severe 
fever with thrombocytopenia syndrome virus, ANDV = Andes virus, EBOV = Ebola virus. 
(C) Statistical Enrichment Analysis was carried out using the Chi-Square Exact Test with 
false discovery rate correction. Each dot represents a unique gene identified from 
integration site mapping in the HAP1-SFTSVR population. The size of the dot, and 
number in parenthesis when provided, reflects the number of unique integration sites 
found within that particular gene. For clarity, only genes with 3 or more unique 
integration sites are plotted. (D) Schematic of glucosylceramide synthesis. GlcCer is 
synthesized by the membrane-bound UGCG on the cytosolic face of the cis-Golgi. The 
polar head of GlcCer is then flipped to the lumenal side by the transporter MDR1, where 
it can be further modified by lactosylceramide synthase (LCS) to form lactosylceramide, 
the core building block of most cellular glycosphingolipids. 
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expansion of surviving colonies, cells were collected and either stored at -80°C for 
additional cellular assays, or genomic DNA was extracted for deep sequencing of the 
vector integration sites.  
 To determine whether the cells surviving rVSV-SFTSV infection were indeed 
refractory to SFTSV-mediated entry, the surviving population and parental HAP1 cells 
were challenged in parallel with a panel of recombinant VSVs (Fig 2-1B).  Infection of 
the surviving population with rVSV-SFTSV was greatly reduced compared to parental 
HAP1 cells, with only 15% residual infection. In contrast, infection with rVSV or an rVSV 
expressing the glycoprotein of Ebola virus instead of VSV G (rVSV-EBOV) was only 
modestly reduced in the surviving population compared to the parental cells. Infection 
with an rVSV expressing the glycoprotein of Andes virus (rVSV-ANDV), a distantly 
related bunyavirus, showed a intermediate phenotype with 32% residual infection, 
suggesting potential overlapping requirements for entry of these bunyaviruses. These 
data indicate that the screen selected pro-viral factors affecting SFTSV entry and not 
VSV replication. 
 Using genomic DNA isolated from the rVSV-SFTS-surviving population, lentiviral 
integration sites were mapped by deep sequencing of HIV-human genome junctions 
(30). The frequency of integration sites within each gene in the surviving population was 
compared to an unselected control population. A Chi-Square Exact Test with false-
discovery rate correction was used to identify genes that were enriched for mutations 
compared to the control (Fig 2-1C). The statistical analysis identified glucosylceramide 
synthase (UGCG, UDP-Glucose Ceramide Glucosyltransferase) as a top hit (p-
value=3.7x10-9), containing 8 independent integration sites in the set of intragenic 
integrations sites in the selected cells (N=4,502).  
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UGCG catalyzes the first step in glycosphingolipid (GSL) biosynthesis, by 
attaching a glucose residue to the 1-hydroxyl group of ceramide, forming 
glucosylceramide (Fig 2-1D). This forms the backbone for subsequent sugar addition 
and modification to form the cellular repertoire of gangliosides and additional GSL 
classes. Given the previously documented roles for glycosphingolipids and other 
glycosylated molecules in virus entry (31-33), we focused our subsequent analysis on 
discerning if UGCG affected SFTSV-glycoprotein mediated entry.  
Genetic manipulation of UGCG validates role for UGCG expression in SFTSV entry 
To determine if UGCG plays a role in SFTSV glycoprotein-mediated entry, two 
unique siRNAs targeting UGCG were tested in parallel with a non-targeting siRNA 
control (Neg Ctrl). U-2 OS cells were transfected with the siRNAs and 72 hours post-
transfection were infected with rVSV-SFTSV or wild-type VSV for a single cycle infection 
(10hr) (Fig 2-2A). The siRNAs targeting UGCG both inhibited rVSV-SFTSV infection 
relative to the non-targeting siRNA, with siUGCG #1 resulting in over 80% reduction in 
infection (p<0.0001, Student’s t-test). No difference in infection levels was observed for 
VSV amongst the negative control and UGCG siRNAs, suggesting that phenotype 
observed with rVSV-SFTSV was due to an entry defect. RT-qPCR for UGCG mRNA and 
western blotting for UGCG protein expression revealed that both siRNAs were effective 
at knocking down UGCG mRNA expression, but siUGCG #1 led to a much greater 
decrease on UGCG protein levels (Fig 2-2B). The weak effect of siUGCG #2 on UGCG 
protein expression correlates with the more modest decrease in infection with rVSV-
SFTSV (Fig 2-2A).  
To validate the requirement for UGCG using another method, a lentiviral shRNA 
construct was used to knockdown UGCG expression. Following transduction with an 
shRNA and 48 hours of puromycin selection to select for the transducing vector, U-2 OS  
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Fig 2-2: RNAi confirms role for UGCG in SFTSV entry. (A) U-2 OS cells were 
transfected with non-targeting (Neg Ctrl) or UGCG siRNAs and 72 hours post-
transfection were infected with rVSV-SFTSV or VSV. Ten hours post-infection cells were 
harvested, immunostained for VSV M expression, and analyzed by flow cytometry. 
Infection levels are normalized to the negative control siRNA and expressed as relative 
infection. Mean ± S.E.M. for 3 independent experiments. (B) RNA was collected in 
parallel at the time of infection from the siRNA treated cells in (A). RT-qPCR was 
performed and UGCG mRNA was normalized to GAPDH mRNA and expressed relative 
to the negative control siRNA. Western Blot for UGCG protein expression shown in the 
inset. (C) U-2 OS cells were transduced with lentiviral shRNA constructs containing 
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scrambled or UGCG-targeting shRNAs. Following puromycin selection, cells were 
infected with rVSV-SFTS, VSV, or SV40 and harvested 10 hours (rVSV-SFTS, VSV) or 
24 hours (SV40) post-infection, immunostained for viral antigen, and quantified by flow 
cytometry. Mean ± S.E.M. for 2 independent experiments. (D) UGCG mRNA levels in 
cells expressing shScrambled and shUGCG were determined by RT-qPCR, normalized 
to GAPDH mRNA levels, and expressed relative to the scrambled shRNA. Mean ± 
S.E.M. for 2 independent experiments. (E) U-2 OS cells transfected with negative control 
or UGCG siRNAs were infected with rVSV-SFTS, VSV, SV40 or Rift Valley Fever Virus 
(RVFV) 72 hours post-transfection. Cells were harvested 10 hours (rVSV-SFTS, VSV, 
RVFV) or 24 hours (SV40) post-infection, immunostained for viral antigen, and analyzed 
by flow cytometry.  Mean ± S.E.M. for 3 independent experiments. (F) U-2 OS cells were 
co-transfected with 7pmol of non-targeting (siNeg Ctrl) or UGCG siRNA (siUGCG) as 
well as 200ng of pCMV-GFP, pCMV-UGCG (wild-type) [WT], or pCMV-UGCG (siRNA-
resistant) [siRNA-R] plasmid. Forty-eight hours post-transfection, cells were infected with 
rVSV-SFTS. Ten hours post-infection cells were harvested, immunostained for VSV M, 
and quantified by flow cytometry. Infection levels are normalized to the non-targeting 
siRNA/pCMV-GFP control. Mean ± S.E.M. for 3 independent experiments. 
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cells were infected with rVSV-SFTS, VSV, or SV40 (Fig 2-2C). Entry of SV40 requires 
the ganglioside GM1, which is in a biosynthetic pathway downstream of UGCG, and thus 
serves as a positive control for knockdown of UGCG activity. The cells receiving the 
shRNA targeting UGCG (shUGCG) showed a 50% decrease in both rVSV-SFTSV and 
SV40 infection compared to cells receiving a scrambled shRNA (shScrambled) (rVSV-
SFTSV p=0.0003, SV40 p=0.0037). This corresponded with an ~50% decrease in 
UGCG mRNA levels (Fig 2-2D). VSV infection was slightly increased in shUGCG cells 
compared to the shScrambled (p=0.0071). 
We next tested whether a distantly related phlebovirus, Rift Valley fever virus 
(RVFV), which has ~35% amino acid similarity to the SFTSV glycoproteins GN and GC, 
was affected by depletion of UGCG using our siRNAs. Similar to previous experiments, 
treatment with siUGCG #1 or #2 resulted in a decrease in rVSV-SFTSV infection 
(p<0.0001), and also reduced infection with SV40 as expected from the shRNA 
experiments (p<0.05) (Fig 2-2E). In contrast, RVFV infection was slightly enhanced in 
UGCG-depleted cells (p<0.01), indicating that the requirement for UGCG does not 
extend to this distantly related phlebovirus.  
To confirm that the observed phenotype of siUGCG #1 knockdown on rVSV-
SFTSV infection was not due to off-target effects, a siRNA-resistant UGCG expression 
vector was generated that contained four silent mutations in the siUGCG #1 binding site. 
Cells were transfected with siNeg Ctrl or siUGCG #1 and either a vector expressing 
GFP, wild-type UGCG (WT), or the siRNA-resistant UGCG (siRNA-R). Forty-eight hours 
post-transfection, cells were infected with rVSV-SFTSV. Overexpression of WT or 
siRNA-R UGCG had no effect on rVSV-SFTSV infection in cells transfected with the 
negative control siRNA. Cells transfected with siUGCG and the GFP vector exhibited an 
80% decrease in infection compared with cells transfected with siNeg Ctrl and GFP. 
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However, expressing wild-type UGCG in siUGCG-treated cells resulted in a slight 
increase (40%) in infection relative to GFP (p=0.28), while expressing the siRNA-
resistant vector resulted in a statistically significant 2.5-fold, or 158%, increase in 
infection compared to GFP (p<0.001), indicating partial rescue with the siRNA-
insensitive UGCG gene. 
UGCG activity is required for efficient SFTSV entry 
To determine whether the enzymatic function of UGCG was essential for the 
observed reduction on rVSV-SFTSV infection, several inhibitors of UGCG were tested. A 
reversible inhibitor, D,L-threo-PDMP (PDMP), was added to A549 cells 24 hours prior to 
infection with rVSV-SFTSV and then maintained in the media throughout the single cycle 
infection (10hrs) (Fig 2-3A). A dose dependent decrease in rVSV-SFTSV infection was 
observed, reaching a 65% reduction at the highest concentration of 25µM (p<0.0001). 
Treatment of cells with high concentrations (>25µM) of PDMP beyond 36 hours resulted 
in noticeable cell death, which has been described previously to be the result of 
increased ceramide accumulation and subsequent activation of apoptotic pathways (34). 
The second compound tested, N-butyldeoxynojirimycin (NB-DNJ, Miglustat), is FDA 
approved for the treatment of a lysosomal storage disorder (Type I Gaucher Disease) 
and did not exhibit cytotoxicity at the concentrations tested. A549 cells were pretreated 
for 24, 48, or 72 hours with a range of concentrations of NB-DNJ (10, 50, 200µM) before 
infection with rVSV-SFTSV in the continued presence of drug (Fig 2-3B). Across all time 
points, a dose-dependent decrease in infection with rVSV-SFTSV was observed, with a 
60% reduction in infection at the highest dose (200µM) after only 24 hours (p<0.0001). A 
greater effect was observed after 48 hours (72% reduction) and was maximally reduced 
by 77% after 72 hours.  
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Fig 2-3: Pharmacological Inhibitors of UGCG Activity Inhibit SFTSV entry. (A) A549 
cells were pre-treated with the UGCG inhibitor D,L-threo-PDMP for 24 hours before 
infection with rVSV-SFTS. Drug was kept in the media throughout the infection. Ten 
hours post-infection cells were harvested, immunostained for VSV M, and analyzed by 
flow cytometry. Mean ± S.E.M. for 3 independent experiments. (B) A549 cells were pre-
treated with the UGCG inhibitor N-butyldeoxynojirimycin-HCl (NB-DNJ) for 24, 48, or 72 
hours before infection with rVSV-SFTS. Drug was kept in the media throughout the 
infection. Ten hours post-infection, cells were harvested, immunostained for VSV M, and 
analyzed by flow cytometry. Mean ± S.E.M. for 3 independent experiments. (C,D) A549 
cells were pre-treated with NB-DNJ (C) or N-(n-Butyl) deoxygalactonojirimycin (NB-DGJ) 
(D) for 48 hours before infection with rVSV-SFTS, VSV, SV40, or RVFV. Drug was kept 
in the media throughout infection. Ten hours (rVSV-SFTS, VSV, RVFV) or 24 hours 
(SV40) post-infection, cells were harvested, immunostained for viral antigen, and 
analyzed by flow cytometry. Mean ± S.E.M. for 3 independent experiments. 
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Since the observed effect on rVSV-SFTSV infection could also be due to a defect 
in replication of the VSV core, cells pretreated with NB-DNJ were infected with wild-type  
VSV. Also, to ensure that NB-DNJ treatment resulted in decreased ganglioside 
production, SV40 infection was used as a control. A549 cells were pretreated with NB-
DNJ for 48 hours before infection with VSV, SV40, RVFV, or rVSV-SFTSV (Fig 2-3C). 
As above, a dose-dependent effect was observed with rVSV-SFTSV (73% decrease at 
200µM, p<0.0001), as well as with SV40 (50% decrease at 200µM, p<0.0001).  There 
was no effect seen on VSV infection levels across the range of NB-DNJ concentrations 
tested (p=0.69 at 200µM), confirming that the phenotype observed with rVSV-SFTSV 
was not due to VSV replication. Similar to the siRNA experiments, RVFV was unaffected 
by NB-DNJ pre-treatment (p=0.49 at 200µM).  
In addition to NB-DNJ, we tested a second imino sugar derivative, N-(n-
butyl)deoxygalactonojirimycin (NB-DGJ), that is a chiral isomer of NB-DNJ with 
enhanced specificity for UGCG. A549 cells were pretreated with NB-DGJ at a range of 
concentrations (10, 50, or 200µM) for 48 hours before infection with the same viruses as 
above (Fig 2-3D). A similar dose-dependent decrease in rVSV-SFTSV and SV40 
infection was observed with NB-DGJ treatment (p<0.0001 at 200µM). No effect was 
seen on VSV and RVFV over the concentrations tested. These data confirm that the 
effect on rVSV-SFTSV and SV40 infection observed with NB-DNJ was due to targeting 
of UGCG enzymatic activity. Together these drug studies indicate that the enzymatic 
activity of UGCG is important for efficient SFTSV entry and that the changes that occur 
within the cell to reduce SFTSV entry efficiency occurs within 24 hours of drug treatment 
(Fig 2-3A,B). The requirement for UGCG activity does not appear to extend to RVFV. 
Additional phleboviruses will need to be tested to fully determine the range of 
dependency. 
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Downstream ganglioside and lactosylceramide biosynthesis does not inhibit 
SFTSV entry 
 Glucosylceramide synthesis is the first step in the production of many 
glycosphingolipid species, including gangliosides (Fig 2-4A). Various gangliosides can 
serve as entry receptors for viruses, such as polyomaviruses and rotaviruses (reviewed 
in 31). To determine if the observed requirement for UGCG in SFTSV entry was due to 
the need for a ganglioside receptor, siRNAs targeting key ganglioside biosynthetic 
enzymes were designed to inhibit various subsets of gangliosides (o-, a-, b-series) (Fig 
2-4B,C). Knockdown of GD3 Synthase (GD3S, ST8SIA1) in U-2 OS cells had no effect 
on SFTSV entry and resulted in rVSV-SFTSV infection levels that were similar to the 
negative control siRNA. In contrast, GD3S siRNA treatment increased SV40 infection 
(3.7-fold, p<0.001). This increase in SV40 infection in GD3S siRNA treated cells likely 
results from diversion of GM3 from the b-series ganglioside path into the a-series 
pathway, which includes the SV40 receptor GM1a. A siRNA targeting GM3 Synthase 
(GM3S, ST3GAL5) was also tested, which results in decreased a- and b-series 
gangliosides, including GM1a. Following GM3S knockdown in U-2 OS cells, infection 
with SV40 was decreased 4.5-fold (p<0.0001), while rVSV-SFTSV infections were again 
similar to the negative control siRNA. For both siRNAs, VSV infection levels also 
remained similar to the negative control siRNA, indicating there was no effect on VSV 
entry or replication. Together, this evidence suggests that complex ganglioside formation 
is not required for rVSV-SFTSV infection.  
 Immediately following glucosylceramide (GlcCer) formation, GlcCer is flipped 
from the cytosolic surface of the Golgi complex to the lumenal surface where a galactose 
moiety is added by lactosylceramide synthase (LCS) to form lactosylceramide (LacCer) 
(Fig 1D). To test whether the formation of the simple glycolipid LacCer was required for  
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Fig 2-4: Analysis of Downstream Glycosphingolipid Biosynthesis. (A) Diagram of 
Ganglioside Biosynthesis. Unique enzymes are responsible for the formation of GlcCer, 
LacCer, GM3 and GD3 (left hand side). These substrates are then modified by common 
enzymes in a step-wise manner to attach additional sugar moieties. Each of the o-, a-, 
and b-series branches are a committed pathway, since sialyltransferases cannot convert 
an a-series ganglioside to a b-series (excluding the conversion of GM3 to GD3). (B) U-2 
OS cells were transfected with siRNAs targeting UGCG, GM3 Synthase (GM3S), GD3 
Synthase (GD3S), or a non-targeting control (Neg Ctrl) and 72 hours later were infected 
with rVSV-SFTS, VSV, or SV40. Ten hours (rVSV-SFTS, VSV) or 24 hours (SV40) post-
infection cells were harvested, immunostained for viral antigen, and analyzed by flow 
cytometry. Mean ± S.E.M. for 3 independent experiments. (C) mRNA levels for UGCG, 
GM3S, and GD3S were determined using RT-qPCR, normalized to GAPDH mRNA 
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levels, and expressed relative to the negative control siRNA. (D) U-2 OS cells were 
transfected with siRNAs targeting UGCG, B4GALT5, B4GALT6, both B4GALT5 and 
B4GALT6 (B4GALT5/6), or a non-targeting control (Neg Ctrl). 72 hours post-transfection 
cells were infected with rVSV-SFTS, VSV, or SV40. Ten hours (rVSV-SFTS, VSV) or 24 
hours (SV40) post-infection cells were harvested, immunostained for viral antigen, and 
analyzed by flow cytometry. Mean ± S.E.M. for 3 independent experiments. (E) mRNA 
levels for UGCG, B4GALT5, and B4GALT6 from siRNA-transfected cells were 
determined by RT-qPCR, normalized to GAPDH mRNA levels, and expressed relative to 
the negative control siRNA.  
  
45 
	  
SFTSV entry, siRNAs targeting LCS were obtained (Fig 2-4D,E). Two cellular LCSs 
exist, B4GALT5 and B4GALT6, with B4GALT5 being more ubiquitous. Knockdown of 
B4GALT5 lead to a 2-fold increase in rVSV-SFTSV infection (p<0.0001), while 
knockdown of B4GALT6 had no effect. In case B4GALT5 can compensate for B4GALT6 
within the cell due to redundant functions, dual knockdown B4GALT5 and B4GALT6 was 
performed. Dual knockdown lead to a 2.7-fold increase in rVSV-SFTSV infection 
(p<0.0001). The observed increases on rVSV-SFTSV infection could potentially be 
caused by increased GlcCer accumulation, although more experiments will be needed to 
address the mechanism for the observed phenotype. Surprisingly, an increase on SV40 
infection was observed with knockdown of B4GALT5 and B4GALT6, but no effect was 
observed when both LCSs were targeted. Surface expression of GM1a in siB4GALT5 
and siB4GALT6-treated cells was increased compared to negative control siRNA and 
siB4GALT5/6 treated cells (data not shown), potentially explaining the observed 
increased in infection with SV40.  
UGCG expression and activity are also required for wild-type SFTSV infection 
 Since the screen and subsequent validation was performed using a recombinant 
virus, it was important to determine if UGCG expression and activity were required by a 
clinical isolate of SFTSV. U-2 OS cells were transfected with siRNAs targeting UGCG 
and infected 72 hours later with SFTSV (strain HB29, MOI 0.1) (Fig 2-5A). The infection 
was allowed to proceed for 48 hours before supernatants were collected and viral titers 
were determined by plaque assay. Similar to what was observed with rVSV-SFTSV (Fig 
2-2A), wild-type SFTSV showed a 75% decrease in infection with siUGCG #1 compared 
to the negative control siRNA (p<0.0001). A less robust decrease was observed with 
siUGCG #2 (35% decrease, p=0.085), again similar to what was observed with rVSV-
SFTSV, and likely due to incomplete knockdown of UGCG protein expression. 
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Fig 2-5: UGCG Activity and Expression Important for wild-type SFTSV infection. 
(A) U-2 OS cells were transfected with siRNAs to UGCG or a non-targeting control and 
72 hours later were infected with SFTSV (strain HB29, MOI 0.1). Supernatants from 
infected cells were collected 48 hours post-infection and viral output was determined by 
plaque assay. Infectious output is expressed relative to the negative control siRNA. (B) 
U-2 OS cells were pre-treated with NB-DNJ for 48 hours before infection with SFTSV 
(MOI 5). Supernatants from infected cells were collected 12 hours post-infection and 
viral output was determined by plaque assay. Infectious output is expressed relative to 
the untreated control.  
  
47 
	  
To test whether UGCG enzymatic activity was required for efficient wild-type 
SFTSV infection, U-2 OS cells were pretreated with NB-DNJ for 48 hours, and then 
infected with SFTSV (strain HB29, MOI 5). Following 12-hours of infection, supernatants 
were collected and viral titers determined by plaque assay. A dose-dependent decrease 
in viral output was observed, with titers being reduced by 80% at the highest dose 
(200µM, p<0.001). Together, these observations suggest that UGCG expression and 
activity are required for efficient replication of wild-type SFTSV. Furthermore, the use of 
rVSV-SFTSV as model for studying SFTSV entry faithfully recapitulates what is seen 
with the wild-type virus. 
Heartland virus also requires UGCG for efficient entry 
 Recently, another tick-borne phlebovirus closely related to SFTSV, Heartland 
Virus (HRTV), was identified as the cause of severe febrile disease in several patients in 
the Midwestern United States (35). HRTV is approximately 80% similar to SFTSV at the 
amino acid level, and groups with SFTSV on a phylogenetic tree of phlebovirus 
glycoprotein amino acid alignments (Fig 2-6A). A codon-optimized version of the 
Heartland Virus glycoprotein (strain MO-4) was synthesized and used to generate 
pseudotypes on a VSV core (VSV-HRTV), similar in structure to our rVSV-SFTSV 
replication-competent virus. U-2 OS cells were treated with siRNAs targeting UGCG and 
infected with VSV-HRTV or rVSV-SFTSV (Fig 2-6B). Infection with VSV-HRTV was 
reduced by 85% in cells treated with siUGCG #1 (p<0.001), similar to the 83% decrease 
observed on rVSV-SFTSV infection. Again, infection of cells treated with siUGCG #2 
exhibited a less robust decrease, but did inhibit VSV-HRTV by 70% (p<0.001) and rVSV-
SFTSV by 59% (p<0.001). UGCG activity was inhibited using NB-DNJ similar to 
previous experiments. Following 48 hours of pre-treatment, U-2 OS cells were infected  
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Fig 2-6: Heartland virus, close relative 
of SFTSV, also requires UGCG for 
efficient entry. (A) Phylogenetic tree 
based on the amino acid alignments of 
various phlebovirus glycoproteins 
(polyprotein precursor). Scale bar 
represents genetic distance as a percent 
difference (0.2 = 20%). Asterisks denote 
virus sequences used to generate codon-
optimized M segments (GN-GC) for the 
present study. (B) U-2 OS cells were 
transfected with siRNAs to UGCG or a 
non-targeting control, then 72 hours later 
were infected with rVSV-SFTSV or the 
VSV pseudotype bearing the Heartland 
virus glycoprotein (VSV-HRTV). Twelve 
hours post-infection cells were harvested, 
immunostained for VSV M, and analyzed 
by flow cytometry. Percent infection was 
normalized to samples receiving the 
negative control siRNA and expressed as 
relative infection. Mean ± S.E.M. for 3 
independent experiments. (C) U-2 OS 
cells were pre-treated with NB-DNJ for 48 
hours before infection with rVSV-SFTS, 
VSV-HRTV or VSV. Drug was kept in the 
media throughout the infection. Twelve 
hours post-infection cells were harvested, 
immunostained for VSV M, and analyzed 
by flow cytometry. Percent infection was 
normalized to the untreated control for 
each virus and expressed as relative 
infection. Mean ± S.E.M. for 3 
independent experiments. 
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with VSV-HRTV or rVSV-SFTSV with drug maintained throughout the infection (Fig 2-
6C). Similar to previous results, rVSV-SFTSV exhibited a dose-dependent decrease in 
infection, and consistent with the siRNA experiment, VSV-HRTV infection was negatively 
impacted by UGCG inhibition with NB-DNJ. At the highest dose of 200µM, VSV-HRTV 
infection levels were reduced by 53% (p<0.001), on par with 50% reduction observed 
with rVSV-SFTS (0<0.001). Together, these results confirm a similar role for UGCG 
expression and activity on the efficient entry of Heartland virus, a phlebovirus closely 
related to SFTSV.   
UGCG inhibition does not affect the binding or internalization of SFTSV 
 Virus entry is described by discrete stages, beginning with binding of the virus to 
a target cell via an attachment factor or receptor. In the case of bunyaviruses, the virion 
must then be internalized by endocytosis and traffic through the endo-lysosomal network 
to a low pH compartment, wherein the glycoprotein undergoes a conformation change 
allowing for fusion of the viral and host membranes (15,36). In order to determine the 
stage of the SFTSV entry process where UGCG is required, a qPCR-based binding and 
internalization assay was employed. The assay can assess relative levels of virus bound 
to and internalized by normal cells compared to those treated with UGCG-targeting 
siRNAs or pharmacological inhibitors of UGCG. Cells were chilled to 4°C on ice for 30 
minutes before rVSV-SFTSV was added and allowed to bind to cells for 1 hour at 4°C. 
Following the first hour, a subset of cells was moved to 37°C to allow internalization of 
bound virions while the remaining cells were left at 4°C. At the conclusion of the second 
hour, cells that were left at 4°C were washed thoroughly with PBS and either directly 
lysed to determine the amount of bound virus, or treated with trypsin, washed, and then 
lysed to remove surface-bound virions in order to define the amount of background in  
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Fig 2-7: Binding and internalization of virus in UGCG-inhibited cells. (A) Binding 
and Internalization Assay. U-2 OS cells were transfected with negative control or UGCG 
siRNAs and the assay was performed 72 hours post-transfection. Cells were pre-chilled 
at 4°C on ice for 30 minutes, then 200µL of diluted virus in cold media was added. 
Following one hour at 4°C to allow binding, one plate was moved to 37°C for one hour to 
allow internalization, while the other plate remained at 4°C for the same hour. Following 
the second hour, cells were washed 3X with PBS, then either immediately lysed, or 
trypsinized for 10 min to remove remaining surface bound virus before lysis. RNA was 
collected and RT-qPCR was performed to measure viral genomes (vRNA). vRNA levels 
were normalized to GAPDH mRNA levels, and are expressed relative to bound vRNA for 
the negative control siRNA. Mean ± S.E.M. for 3 independent experiments. Bound = 
4°C, direct lysis; Background = 4°C, trypsin then lysis; Internalized = 37°C, trypsin then 
lysis. (B) RNA collected from (A) was also analyzed for UGCG mRNA expression. 
UGCG mRNA levels were measured by RT-qPCR, normalized to GAPDH mRNA levels, 
and expressed relative to the negative control siRNA (bound). (C,D) The binding and 
internalization assay was carried out essentially as in (A) with the exception that U-2 OS 
cells were instead pre-treated with NB-DNJ for 48 hours prior to binding with rVSV-
SFTSV (C) or SV40 (D) and qPCR for SV40 genomes did not require reverse 
transcription. Mean ± S.E.M. for 3 independent experiments.   
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the assay. The cells that had been warmed to 37°C were also trypsinized, washed and 
then lysed, providing a measure of the amount of internalized virus. Primers that anneal 
to the negative-strand viral genome were used for reverse-transcription and quantitative 
PCR.  
 U-2 OS cells were transfected with siRNAs either targeting UGCG (siUGCG #1) 
or a non-targeting control (siNeg Ctrl), and 3 days later were used to assess binding and 
internalization levels of rVSV-SFTSV (Fig 2-7A). Despite efficient knockdown of UGCG 
in siRNA-transfected cells as measured by qPCR (Fig 2-7B), there was no observable 
difference in the efficiency of binding or internalization of rVSV-SFTSV between siRNA 
treatments. To ensure that this stage of viral entry was indeed unaffected by UGCG 
inhibition, the assay was repeated with the UGCG inhibitor NB-DNJ. U-2 OS cells were 
pretreated with NB-DNJ or left untreated for 48 hours before being used to assess 
binding and internalization levels for rVSV-SFTSV (Fig 2-7C). Similar to the siRNA-
treated cells, there was no observable difference in the relative amount of bound or 
internalized rVSV-SFTSV in untreated or NB-DNJ-treated cells, suggesting that these 
early steps in SFTSV entry are not impacted by UGCG inhibition. To verify that the 
qPCR assay was indeed robust and the observed results with rVSV-SFTSV were 
accurate, SV40 binding and internalization was measured (Fig 2-7D). Since NB-DNJ 
treatment results in decreased synthesis of GM1a and SV40 requires GM1a as its 
receptor, SV40 should exhibit reduced binding in NB-DNJ-treated cells compared to 
untreated cells. Consistent with this hypothesis, SV40 binding was significantly reduced 
by 36% in NB-DNJ treated cells compared to the untreated control (p<0.01). As 
anticipated because of the reduced binding, internalization of SV40 was also decreased 
by 42% with NB-DNJ treatment though the observed difference was not statistically 
significant (p=0.17). Together, these data demonstrate that UGCG does not function in 
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the very early steps of virus entry for SFTSV, including binding and internalization, and 
suggests a role in trafficking or penetration of incoming virions.  
Inhibition of UGCG activity causes virus accumulation at late stages of entry 
 Previous studies on the entry of SFTSV (20,21) have found that, similar to other 
bunyaviruses (36), SFTSV requires endocytosis via a dynamin-dependent mechanism 
and endosomal acidification for entry. Investigations by Lozach et al using the distantly 
related phlebovirus, Uukuniemi virus (~38% glycoprotein a.a. similarity), have observed 
trafficking of incoming virions through Rab5, Rab7 and LAMP1-positive endosomes, 
respectively (37). However, no detailed studies on the trafficking of incoming SFTSV 
virions have been reported.  
 In order to determine if inhibition of UGCG activity was interfering with the 
trafficking or localization of incoming virions, immunofluorescence microscopy was used 
to observe internalized virus particles within the endo-lysosomal network. Briefly, A549 
cells plated on glass coverslips were treated with NB-DNJ (200µM) for 48 hours or left 
untreated. After 48 hours, cells were chilled for 30 minutes on ice at 4°C to inhibit 
endocytosis, before addition of rVSV-SFTSV in chilled media and binding of virions by 
centrifugation (1200xg) for 30 minutes at 4°C. Following centrifugation, media was 
replaced with pre-warmed media (37°C) and placed in a 37°C incubator for the indicated 
length of time before fixation and immunostaining for viral antigen and various cellular 
markers. At ten minutes post-warming, rVSV-SFTSV could be visualized entering 
EEA1+ early endosomes (data not shown), and co-localization of virions with EEA1 
greatly increased at 20 minutes post-warming (Fig 2-8A). Virus was observed to 
populate EEA1+ early endosomes similarly between untreated and NB-DNJ treated 
cells. No appreciable co-localization was seen between rVSV-SFTSV and Rab7 or 
LAMP1 at 20 minutes in either untreated or NB-DNJ treated cells (data not shown). Virus  
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Fig 2-8: Immunofluorescence microscopy of incoming virus particles, 20 minutes. 
(A, B) A549 cells were plated onto glass coverslips and the following day replaced with 
media containing NB-DNJ (200µM) or left untreated. Forty-eight hours later, cells were 
chilled to 4°C on ice, then rVSV-SFTSV was bound by centrifugation (1200xg, 30’, 4°C). 
Following centrifugation, media was replaced with pre-warmed media (37°C) and the 
cells placed in a 37°C incubator for 20 minutes before fixation in 2% paraformaldehyde 
for 10 minutes. Cells were then immunostained for viral antigen (anti-VSV M, red), 
cellular markers (green), and nuclei stained with DAPI (blue). Images are representative 
from at least 3 independent experiments. (A) A549 cells co-stained for rVSV-SFTSV 
(red) and early endosome marker EEA1 (green). (B) A549 cells co-stained for rVSV-
SFTSV (red) and trans-Golgi marker TGN46 (green). Scale bar represents 5µm. 
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was observed to co-localize with the trans-Golgi complex marker TGN46 at 20 minutes 
under both treatment conditions (Fig 2-8B).  
At 40 minutes post-warming in untreated A549 cells, rVSV-SFTSV was still 
observed in EEA1+ endosomes, although with less frequency (Fig 2-9A, top panels). 
Instead, virus appeared to localize with greater concentration in TGN46+ compartments 
(Fig 2-9B, top panels), suggesting movement from the early endosomes to the trans-
Golgi, either directly or through a circuitous route. Additionally, extensive co-localization 
was not seen between rVSV-SFTSV and Rab7 or LAMP1 at 40 minutes post-warming, 
similar to the 20-minute time point (Fig S2-1).  
 In contrast to untreated cells, at 40 minutes post-warming in NB-DNJ treated 
cells, rVSV-SFTSV was observed to accumulate within a vesicular compartment (Fig 2-
9A-B, bottom left panels). This compartment appeared to have markers of both EEA1 
(Fig 2-9A, bottom panels) and TGN46 (Fig 2-9B, bottom panels), although not 
exclusively. The virus containing compartment(s) can be seen with and without EEA1 or 
TGN46, and the marker does not appear to completely envelop the compartment, 
suggesting a more complex composition. Due to antibody cross-reactivity, co-staining for 
both EEA1 and TGN46 within the same infected cell was not possible. Additionally, viral 
accumulation was also observed at 40 minutes post-warming in A549 cells pre-treated 
with the highly specific UGCG inhibitor NB-DGJ (Fig S2-2).  
 In order to quantify the accumulation of incoming virions, the volume of rVSV-
SFTSV-positive puncta was measured by quantitative image analysis. Intensity and 
volume cutoffs were determined based on immunostaining for viral antigen in uninfected 
cells and set to exclude >99% of background staining. At 20 minutes post-warming, no 
significant difference in rVSV-SFTSV virions volumes between untreated and NB-DNJ 
treated cells was observed (Fig 2-9C). However, at 40 minutes post-warming the virion  
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Fig 2-9: Immunofluorescence microscopy and quantification of incoming virus 
particles. (A, B) A549 cells prepared as described in Fig 8 were fixed 40 minutes post-
warming and co-stained for rVSV-SFTSV (red) and the early endosome marker EEA1 
(green) (A) or TGN46 (B). Cells were treated with NB-DNJ (bottom panels) or left 
untreated (top panels). Scale bar represents 5µm. (C, D) Quantitative image analysis 
was performed to measure the volume of discrete VSV M-stained puncta within z-stack 
images in untreated and NB-DNJ treated cells at both 20 and 40 minutes post-warming. 
Puncta were counted for at least 6 independent z-stacks per sample for both rVSV-
SFTSV (C) and VSV (D) infected cells. (**** p<0.0001 using Welch’s one-tailed t-test) 
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puncta volumes in NB-DNJ treated cells were significantly greater than those in 
untreated cells (p<0.0001, one-tailed Welch’s t-test). In order to ensure the observed 
phenotype was specific to the SFTSV glycoprotein, virion puncta volumes were also 
calculated for wild-type VSV-infected cells with or without NB-DNJ pre-treatment. As 
expected based on the previous infection data, VSV virion puncta volumes were not 
significantly different between untreated and NB-DNJ treated cells at 20 minutes or 40 
minutes post-warming (Fig 2-9D, S2-3). Taken together, these data suggest that 
incoming rVSV-SFTSV virions enter the early endosome (EEA1+) and, by an 
unidentified route and mechanism, traffic to the trans-Golgi (TGN46+). While rVSV-
SFTSV virions appear in similar compartments under normal conditions or in the 
presence of UGCG inhibitors, the latter condition causes the accumulation of rVSV-
SFTSV virions.  
 
Section 2.4 – Discussion 
 Genetic screens in haploid human cells are a powerful approach for elucidating 
virus-host interactions, including identifying critical cellular factors in the virus entry 
process. Several HAP1 screens have used replication-competent, recombinant vesicular 
stomatitis viruses (rVSV) encoding orthogonal glycoproteins to discover cellular factors 
required for the entry of highly pathogenic viruses, including Ebola (26), Andes (27,28), 
and Lassa viruses (38,39). The present study utilized an rVSV encoding the glycoprotein 
of the newly emerged bunyavirus, SFTS virus (rVSV-SFTSV). Challenge of the HAP1 
library with rVSV-SFTSV led to a significant enrichment in cells harboring mutations in 
glucosylceramide synthase (UGCG), a critical component of cellular glycosphingolipid 
(GSL) biosynthesis. GSLs have been implicated as receptors or attachment factors for a 
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number of different viruses, including the polyomaviruses SV40 (GM1a) and BK virus 
(GD1b, GT1b), human rotavirus (GM1, histo-blood group antigens [HBGA]), and human 
norovirus (HBGA) (32,40-44). We showed that UGCG expression and enzymatic activity 
are important for SFTSV entry, using both rVSV-SFTSV and wild-type SFTSV infection. 
Additionally, using pseudotypes bearing the glycoproteins of the closely related 
Heartland virus, we showed that entry of this emerging virus endemic to the United 
States was also sensitive to UGCG perturbation.   
 Given the role of UGCG in GSL biosynthesis, we sought to determine if, similar 
to the non-envelope viruses previously mentioned, SFTSV also required complex 
ganglioside formation for entry. siRNAs targeting key ganglioside synthesis enzymes did 
not affect SFTSV entry. Furthermore, pre-incubating virus with a mixture of complex 
gangliosides (predominantly GM1a, GD1a, GD1b, GT1b) before infection of U2OS cells 
did not neutralize rVSV-SFTSV infection, although it did neutralize SV40 in a dose-
dependent manner (data not shown). These observations confirm that complex 
ganglioside formation is not necessary for efficient SFTSV entry. However, a number of 
other GSL species containing different glycosylated cores, such as the globo-series and 
lacto-series GSLs, were not tested in the present study. 
 Following GlcCer synthesis by UGCG on the cytosolic face of the cis-Golgi, 
GlcCer is flipped to the lumenal membrane by MDR1 where lactosylceramide synthase 
(B4GALT5, B4GALT6) appends a galactose moiety to the terminal glucose (45-47). 
Inhibition of lactosylceramide synthase leads to the accumulation of GlcCer (48,49), and 
we observed an increase in SFTSV infection when B4GALT5 or B4GALT5 in conjunction 
with B4GALT6 were down regulated using siRNAs (Fig 2-4D). Surprisingly, infection with 
SV40 was also increased when B4GALT5 or B4GALT6 was inhibited, even though 
GM1a synthesis is downstream of LacCer synthesis. Staining cells treated with 
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siB4GALT5 or siB4GALT6 with fluorescently-tagged cholera toxin subunit B, which also 
binds to GM1a, was increased compared to cells treated with a non-targeting siRNA or 
siRNAs to both lactosylceramide synthases (data not shown). This could potentially 
explain the increase in SV40 infection, such that within the time scale of the siRNA 
knockdown (72 hours) GSL recycling may compensate for inhibition of de novo GSL 
synthesis. More investigations are needed to fully determine the role of GlcCer 
accumulation and LacCer down-regulation on SFTSV infection, and the role that 
B4GALT5/6 inhibition plays on the cellular homeostasis of GSL formation.  
 The entry process for enveloped viruses can be described by discrete stages, 
beginning with the binding or attachment of virus particles to the host cell surface. For 
viruses requiring endocytosis, binding to an attachment factor or receptor leads to 
internalization of the virus particle. The virus will then traffic within the endo-lysosomal 
network to reach the proper environment (e.g. providing proper low pH, protease 
cleavage, intracellular receptor, or lipid composition) where the viral and host membrane 
fusion is triggered, releasing the genomic contents into the cytoplasm for replication. In 
order to determine if UGCG functionally played a role in the binding or internalization of 
SFTSV, we performed a qPCR-based binding and internalization assay using cells 
treated with siRNAs targeting UGCG or a pharmacological inhibitor of UGCG (NB-DNJ). 
Under both conditions, neither the binding nor the internalization of rVSV-SFTSV virions 
was affected by UGCG inhibition. This suggests that UGCG inhibition impedes a post-
internalization stage of the entry process. Potential stages include the trafficking of 
internalized virions to a particular location, priming or maturation of the viral envelope, 
and/or the fusion of virus-host membranes.  
 The endocytic trafficking requirements for several bunyaviruses have been 
investigated, but this study is the first report examining SFTSV glycoprotein-mediated 
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entry. Studies with the phlebovirus Uukuniemi virus (UUKV) by Lozach et al sequentially 
observed UUKV particles in Rab5a, Rab7a, and LAMP1-positive compartments, 
suggesting UUKV is a late-penetrating virus (37). In contrast, the orthobunyavirus 
LaCrosse virus (LACV) and the nairovirus Crimean-Congo hemorrhagic fever virus 
(CCHFV) were found to only require trafficking to early endosomes and multi-vesicular 
bodies, respectively (50-52). In all cases, trafficking into early endosomes was required. 
Similarly, in the present study we observed rVSV-SFTSV virions co-localizing with the 
early endosome marker EEA1 as early as 10 minutes post-warming, with considerable 
co-localization at 20 minutes post-warming (Fig 2-8A). Minimal co-localization of virions 
with Rab7 or LAMP1 was observed at 20 and 40 minutes post-warming (Fig S2-1), 
suggesting SFTSV does not require trafficking to these compartments. In the case of 
UUKV, despite being observed in Rab7a+ compartments, expression of the dominant 
negative Rab7a T22N mutant had no effect on UUKV infection, nor did it inhibit LACV or 
CCHFV infection (37,50,51). Further investigation is needed to clarify the requirement of 
Rab7a on SFTSV entry. We observed co-localization of rVSV-SFTSV virions with the 
trans-Golgi marker TGN46 as early as 20 minutes post-warming, and with increased 
concentration at 40 minutes post-warming (Fig 2-8B, 2-9B). Trafficking of incoming 
bunyaviruses to the Golgi complex has not been previously reported. Interestingly, 
nascent bunyaviral proteins are assembled in the Golgi complex to form progeny virions 
(15), potentially revealing a link between virus entry and the establishment of replication. 
Other viruses have been reported to require trafficking to the Golgi for entry, for example 
human papilloma virus 16 interacts with retromer to escape the early endosome and 
traffic to the trans-Golgi (53). Further investigations will be needed to discern the 
mechanisms by which SFTSV virions reach the Golgi complex and if this has been an 
overlooked aspect of entry with other bunyaviruses.  
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 Using the previous observations as a foundation, we sought to determine if 
pharmacological inhibition of UGCG altered the trafficking of incoming rVSV-SFTSV 
particles. At 20 minutes post-warming, virions were observed to similarly populate 
EEA1+ endosomes and to a lesser extent, TGN46+ compartments (Fig 2-8A,B). 
Following 40 minutes post-warming, virus particles again co-stained with EEA1 and 
TGN46, but large punctate viral complexes were observed in NB-DNJ and NB-DGJ 
treated cells (Fig 2-9A,B and S2-2), while untreated cells contained only small punctate 
virions. Volumetric analysis of virus immunostaining in z-stack images revealed a 
statistically significant increase in the fluorescent volume of particle puncta in drug-
treated cells compared to untreated, suggesting the accumulation of virions within a 
vesicular compartment. The viral aggregates appeared to share similar markers to 
virions in untreated cells (EEA1, TGN46), suggesting that the virions are not overtly 
mislocalized. However, the composition of the compartment may be altered, thus 
preventing viral fusion and escape or further trafficking to a downstream location.  
 Investigations into the role of GlcCer on endocytic trafficking have found that 
depletion of GlcCer pools with PDMP or NB-DGJ treatment results in disrupted GSL 
recycling to the Golgi and leads to the accumulation of GSLs and cholesterol in 
lysosomes (54). Furthermore, UGCG inhibition leads to increased lysosomal pH by up to 
1 pH unit (55), potentially inhibiting the activity of pH-dependent lysosomal proteases 
and leading to the accumulation of cholesterol. The altered lipid composition of the 
lysosome due to GSL and cholesterol accumulation, increase in lysosomal pH, and 
disrupted recycling to the Golgi could, in a non-mutually exclusive manner, be causing 
the observed accumulation of rVSV-SFTSV virions in GlcCer depleted cells. Given that 
bunyavirus glycoproteins have been shown to undergo pH dependent conformational 
changes (56), and that low pH as well as an unidentified serine protease are required for 
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efficient SFTSV entry (20,21), we propose a model whereby SFTSV traffics through the 
endo-lysosomal network to undergo a pH-dependent conformational change and/or 
protease cleavage of the glycoprotein(s), then continues to the Golgi where fusion is 
triggered, potentially mediated by interaction with a Golgi-resident macromolecule. In the 
case of GlcCer depletion, the endo-lysosomal pH is elevated, which can also mislocalize 
or inhibit proteases, thus preventing the priming or maturation of the viral glycoprotein 
and subsequently prevent efficient fusion of the virus, leading to its accumulation. 
Further studies are needed to investigate this hypothesis.   
 The Phlebovirus genus within the family Bunyaviridae is comprised of 10 species 
and over 50 virus members (57). Phleboviruses can be generally subdivided into the 
phlebotomine/mosquito-transmitted viruses, which includes Rift Valley fever virus, and 
the tick-transmitted viruses, for which the archetype is Uukuniemi virus. SFTSV forms a 
unique species within the tick-transmitted viruses, which also includes Heartland Virus. 
While HRTV entry was sensitive to perturbations to UGCG, RVFV was unaffected. A 
recently published haploid genetic screen using the MP-12 strain of RVFV found 
glycosaminoglycan (GAG) biogenesis, and specifically heparan sulfate formation, as 
being important for RVFV infection (58). The two haploid screens did not share any 
overlapping hits, which suggests that these two distantly related viruses have distinct 
entry requirements. This may be due to the difference in the arthropod vector. More 
extensive studies are underway to determine if the requirement for UGCG is limited to 
the SFTSV phlebovirus species, or extends to other tick-borne phleboviruses. 
Interestingly, ticks also encode a homolog of UGCG and are able to synthesize 
glycosphingolipids. Certain tick cells lines, including those belonging to the Ixodidae 
family, are amenable to siRNA knockdown and future investigations will assess whether 
UGCG is important for infection with SFTSV within its arthropod vector.   
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 Ours is the first reported forward genetic screen seeking to identify host 
requirements for SFTSV entry. Our screen identified a crucial role for GlcCer formation 
in the efficient entry of SFTSV, with GlcCer depletion resulting in the aggregation of virus 
particles during the entry process. Further investigations are needed to fully characterize 
the trafficking of SFTSV virions using labeled particles and live-cell microscopy and to 
identify the compartment in which SFTSV fusion occurs.   
 
Section 2.5 – Materials & Methods 
Cells, Viruses, and Chemicals 
A549 and U-2 OS cells were cultured in DMEM supplemented with 10% FBS, 
while HAP1 cells were cultured in IMDM supplemented with 15% FBS, L-glutamine, and 
P/S. Replication-competent rVSV-SFTSV was generated as described below. VSV and 
rVSV-SFTSV stocks were propagated in Vero cells. SV40 was a kind gift from Dr. James 
Alwine (U. Pennsylvania) and Rift Valley fever virus was generously provided by Dr. 
Robert Doms (Children’s Hospital of Philadelphia). The SFTSV strain (HB29) used in 
these studies is a plaque-purified cell culture-adapted strain initially isolated from a 
patient. The clinical isolate was minimally passaged before plaque purification and has 
been propagated in Vero E6 cells. All siRNAs were purchased from Ambion and 
resuspended according to the manufacture’s instructions. The UGCG inhibitor D,L-threo-
PDMP (Cayman Chemicals) was dissolved in Argon-purged DMSO, aliquoted, and 
stored at -20°C under inert gas. Both N-butyldeoxynojirimycin-HCl and n-(N-butyl) 
deoxygalactonojirimycin (Toronto Research Chemicals) were dissolved in water, 
aliquoted, and stored at -20°C. 
Generation of Recombinant Viruses and Pseudotypes 
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 Replication recombinant vesicular stomatitis viruses were cloned and infectious 
virus rescued as described previously with slight modifications (59). Briefly, a codon-
optimized version of the SFTSV M segment (strain HB29) was synthesized 
(ThermoFisher GeneArt) and cloned into a DNA plasmid of the VSV anti-genome 
between the M and L proteins, in place of VSV G. 293T cells were first infected with 
MVA expressing T7 polymerase for 1 hour, washed 1X, and then transfected with the 
T7-driven rVSV-SFTSV anti-genome plasmid and helper plasmids encoding VSV N, P, 
and L (all pCAGGS). Media was changed the following day, and 48 hours post-
transfection supernatants were collected, transferred to Vero cells, and passaged 3 
times before collection of virus stocks.  
 VSV-HRTV psedudotypes were generated as described previously (60). A 
codon-optimized version of the HRTV M segment (strain MO-4) was synthesized 
(ThermoFisher GeneArt) and cloned into pCAGGS. 293T cells were transfected with 
pCAGGS-HRTV and 18 hours later transduced with VSV-ΔG-RFP pseudotypes 
previously complemented with VSV G. Since the pseudovirion genome does not encode 
a glycoprotein, progeny virions are complemented with HRTV GN-GC. Supernatants were 
collected 36 hours post-transduction, aliquoted and stored at -80°C.  
HAP1 Genetic Screen & Statistical Analysis 
 HAP1 cells were passaged, enriched for haploid cells, and mutagenized using a 
lentiviral gene-trap vector as described previously (27). 75 millions cells from the HAP1 
gene-trapped library were thawed, allowed to recover for 48 hours, then infected with 
rVSV-SFTSV (MOI 1) by spinfection (1200g, 30m, 21°C). Surviving cells were allowed to 
expand for 14 days before being trypsinized and pooled. A portion of the cells were 
stored at -80°C for cellular assays, while DNA was extracted from the remaining cells for 
integration site analysis. Deep sequencing of lentiviral integration sites was conducted 
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as described ((30) with the exception that sonication rather than restriction enzymes was 
used to fragment genomic DNA and sequencing was performed using an Illumina 
MiSeq. The frequency of independent integration sites within each RefSeq annotated 
gene was determined for both the rVSV-SFTS-selected population (N=4,502) and the 
unselected library (N=803,369). A Chi-Square Exact Test with False-Discover Rate 
correction was used to determine whether a given gene contained more integration sites 
in the selected population than expected based on the unselected library. A p-value of 
0.05 or less was used as the cut-off for significance. 
RNAi Infection Experiments 
For siRNA experiments, 10pmol of siRNA (Ambion) was co-incubated with with 
1.5µL of Lipofectamine RNAiMAX in 200µL of Opti-MEM for 20 minutes before the 
addition of 200,000 U-2 OS cells diluted in DMEM (10% FBS). The cell-transfection 
mixture was then plated into one well of a 12-well plate, re-plated the following day, and 
infected 72 hours post-transfection. Virus was diluted in DMEM (10% FBS) and used to 
spinfect cells (1200xg, 30 minutes, RT). Virus was added to achieve 15-30% infection of 
cells in negative control or untreated samples. Following a single-cycle infection (10 
hours), cells were collected, fixed in paraformaldehyde, immunostained for viral antigen, 
and the percentage of infected cells was quantified by flow cytometric analysis (≥104 
events).  
Plasmids containing lentiviral shRNAs to UGCG or a Scrambled control were 
kindly provided by Dr. Daniel DiMaio (Yale). Lentiviral pseudotypes were generated in 
293T cells by co-transfection of pSIREN-shRNA, pSPAX, and pCAGGS-VSV G. Forty-
eight hours post-transfection supernatants were collected and used to transduced U2OS 
cells. Following 4 days of puromycin selection, cells harboring the shRNA constructs 
were used for virus infection experiments as described above. In parallel with the 
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harvesting of virus-infected cells, RNA extracts were collected according to 
manufacture’s instructions (Qiagen RNeasy) to assess relative mRNA expression of 
genes of interest by RT-qPCR. Following cDNA synthesis (Invitrogen First-Strand 
Synthesis Kit) using random hexamers, qPCR reactions were set up using 10µL Power 
SYBR Green PCR Mastermix, 2µL cDNA, 2µL each Forward and Reverse primers 
(5µM), and 4µL water and run on a 7900HT Fast Real-Time PCR Machine (Applied 
Biosystems) 
UGCG siRNA Rescue 
U-2 OS cells were plated at 50,000/well in a 24 well the evening prior to 
transfection. The next day, U-2 OS cells were transfected (Lipofectamine 2000) with 
7pmol of siNeg Ctrl or siUGCG as well as 200ng of pCMV-UGCG (Ori-gene), pCMV-
UGCG containing 4 silent mutations in the siUGCG binding site (pUGCG-siR), or a GFP-
expressing plasmid control. Forty-eight hours post-transfection cells were infected with 
rVSV-SFTSV or protein lysates were collected for Western Blot analysis. Cells were 
infected by spinfection (1200g, 30min, RT), harvested 10 hours later (single cycle), 
immunostained for VSV M antigen, and the percent of infected cells was quantified using 
flow cytometric analysis (≥104 events).  
UGCG Inhibitor Infections 
 A549 or U-2 OS cells were plated at 40,000 cells/well in 24-well dishes the 
evening prior to drug addition. The next morning, inhibitors were diluted in DMEM (10% 
FBS) and added to cells. Following pre-treatment for 24-72 hours (specific interval 
indicated in Figure Legend), virus was diluted in media containing drug and used to 
spinfect cells (1200g, 30min, RT). Virus was added to achieve 15-30% infection of cells 
in untreated samples. Virus and drug was left on cells during the course of infection. 
After a single replication cycle, cells were collected, fixed with paraformaldehyde, 
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immunostained for viral antigen, and the percent of infected cells was quantified using 
flow cytometric analysis (≥104 events). 
Binding & Internalization Assay 
U-2 OS cells were either transfected with siRNAs 72 hours prior to the assay or 
pre-treated with NB-DNJ for 48 hours prior. Cells were first chilled to 4°C on ice for 30 
minutes to inhibit endocytosis before media was replaced with rVSV-SFTSV or SV40 
diluted in cold DMEM (2% FBS). Virus was allowed to bind to cells for 1 hour at 4°C, 
then cells either remained at 4°C for an additional hour or were moved to 37°C for the 
second hour to permit internalization. At the end of the second hour, cells kept at 4°C 
were either washed 3X with PBS and directly lysed, or washed, trypsinized for 10 
minutes, washed 3X, and then lysed to measure levels of bound virus and background 
virus signal, respectively. Cells that were moved to 37°C were washed 3X, typsinized to 
remove surface-bound virions, washed 3X, then lysed in order to determine levels of 
internalized virus. RNA (rVSV-SFTS) or DNA (SV40) extractions were performed on cell 
lysates according to the manufacturer’s instructions (Qiagen). RNA from rVSV-SFTSV 
samples was reverse-transcribed with random hexamers using the First-Strand 
Synthesis Kit (Invitrogen) while DNA from SV40 samples was used directly for qPCR. 
qPCR reactions were run on a 7900HT Fast Real-Time PCR Machine (Applied 
Biosystems). Viral genomes were normalized to GAPDH by the 2-ΔΔCt method (61). 
Immunofluorescence Microscopy 
 A549 cells were plated on glass coverslips (10,000/well) the evening prior to 
initiating drug treatment. The following morning, N-butyldeoxynojirimycin-HCl (200µM) 
was added to cells. Following 48-hours of pre-treatment, cells were chilled on ice at 4°C 
for 30 minutes to inhibit endocytosis. Media was then replaced with rVSV-SFTSV (MOI 
50) diluted in cold DMEM (2% FBS) and bound to cells by centrifugation (1200xg, 30 
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minutes, 4°C). Following centrifugation, cells washed 1X with cold PBS, replaced with 
warm media (37°C), and placed in a 37°C incubator for various lengths of time (10-40 
minutes). At indicated time points, cells were washed 3X with cold PBS then fixed with 
2% paraformaldehyde for 10 minutes. Cells were washed 3X with PBS, permeabilized 
with 0.1% saponin for 10 minutes, then blocked for 30 minutes in PBST (0.1% Tween) 
with 1% BSA and 0.3M glycine. Coverslips were then incubated in primary antibody 
diluted in PBST and 1% BSA overnight at 4°C, then incubated with secondary antibody 
for 1 hour at room temperature before mounting onto glass slides. Cells were imaged 
using a Leica DM6000 widefield microscope and Photometrics HQ2 CCD camera. 
Images were deconvolved using AutoQuant deconvolution package (Leica) and 
brightness/contrast was adjusted using FIJI (ImageJ). Volumetric analysis of fluorescent 
VSV-M stained puncta was performed using Volocity (Perkin Elmer). Intensity and size 
thresholds were set based on uninfected cells stained for viral antigen and excluded 
>99% of background events. 
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Section 2.6 – Supplemental Figures 
 
Fig S2-1. Immunofluorescence microscopy of incoming rVSV-SFTSV virions with 
markers for Rab7 and LAMP1. (A, B) A549 cells were plated onto glass coverslips and 
the following day replaced with media containing NB-DNJ (200µM) or left untreated. 
Forty-eight hours later, cells were chilled to 4°C on ice for 30 minutes, then rVSV-SFTSV 
was diluted in 250µL of cold media and bound to the surface of cells by centrifugation 
(1200xg, 30’, 4°C). Following centrifugation, media was replaced with pre-warmed 
media (37°C) and the cells placed in a 37°C incubator for 40 minutes before fixation in 
2% paraformaldehyde for 10 minutes. Cells were then immunostained for viral antigen 
(anti-VSV M, red), Rab7 (A) or LAMP1 (B) (green), and nuclei stained with DAPI (blue). 
Coverslips were then mounted on glass slides and imaged using a widefield microscope 
(Leica D6000) with deconvolution. Images are representative from at least 3 
independent experiments. Scale bar represents 5µm.  
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Fig S2-2: Inhibition of UGCG using imino surge derivatives NB-DNJ and NB-DGJ 
leads to accumulation of rVSV-SFTSV virions at late time points. A549 cells were 
plated on glass coverslips and the following day n-butyldeoxynojirimycin (NB-DNJ) or N-
(n-Butyl)deoxygalactonojirimycin (NB-DGJ) (200µM) was added. Forty-eight hours later, 
cells were chilled to 4°C on ice for 30 minutes, then rVSV-SFTSV was diluted in 250µL 
of cold media and bound to the surface of cells by centrifugation (1200xg, 30’, 4°C). 
Following centrifugation, media was replaced with pre-warmed media (37°C) and the 
cells placed in a 37°C incubator for 40 minutes before fixation in 2% paraformaldehyde 
for 10 minutes. Cells were then immunostained for viral antigen (anti-VSV M, red) and 
nuclei were stained with DAPI (blue). Coverslips were then mounted on glass slides and 
imaged using a widefield microscope (Leica D600) with deconvolution. Images are 
representative from at least 2 independent experiments. Scale bar represents 5µm. 
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Fig S2-3. NB-DNJ treatment leads to accumulation of rVSV-SFTSV virions but not 
VSV virions at late time points. (A, B) A549 cells were plated onto glass coverslips 
and the following day replaced with media containing NB-DNJ (200µM) or left untreated. 
Forty-eight hours later, cells were chilled to 4°C on ice for 30 minutes, then rVSV-SFTSV 
(A) or VSV (B) was diluted in 250µL of cold media and bound to the surface of cells by 
centrifugation (1200xg, 30’, 4°C). Following centrifugation, media was replaced with pre-
warmed media (37°C) and the cells placed in a 37°C incubator for 40 minutes before 
fixation in 2% paraformaldehyde for 10 minutes. Cells were then immunostained for viral 
antigen (anti-VSV M, red) and nuclei stained with DAPI (blue). Coverslips were then 
mounted on glass slides and imaged using a widefield microscope (Leica D6000) with 
deconvolution. Images are representative from at least 3 independent experiments. 
Scale bar represents 5µm. 
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CHAPTER 3 
 
 
 
THE MAJOR CELLULAR STEROL REGULATORY PATHWAY IS REQUIRED FOR 
ANDES VIRUS INFECTION 
 
 
 
Reprinted with minor changes from the published manuscript: 
Petersen J*, Drake MJ*, Bruce EA*, Riblett AM, Didigu, CA, Wilen CB, Malani N, Male F, 
Lee FH, Bushman FD, Cherry S, Doms RW, Bates P, Briley KE (2014) The Major 
Cellular Sterol Regulatory Pathway is Required for Andes Virus Infection. PLoS 
Pathogens 10(2): e1003911. doi:10.1371/journal.ppat.1003911 
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with rVSV-ANDV. I subsequently prepared the DNA libraries for deep sequencing of 
integration sites in the rVSV-ANDV-resistant population as well as the unselected control 
population. I performed single cell cloning of cells surviving rVSV-ANDV challenge, 
isolating and validating a S1P-null clone that was later used for the binding and 
internalization assay. I characterized the S1P-, S2P-, and SCAP-null CHO cell lines that 
were provided to us by Michael Brown and Joseph Goldstein. Furthermore, I performed 
cholesterol quantification assays to measure the impact of pharmacological agents on 
cellular cholesterol levels. Lastly, I performed the ANDV entry kinetics experiments to 
show that virus fusion occurs by 3 hours post-infection and that the virus inhibition seen 
with a S1P inhibitor is not due to delayed fusion kinetics. In addition to the experiments I 
performed, I participated fully in the design of experiments, data analysis, critical 
discussions related to the project, and writing of this manuscript.  
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Section 3.1 – Abstract  
 
The Bunyaviridae comprise a large family of RNA viruses with worldwide 
distribution and includes the pathogenic New World hantavirus, Andes virus (ANDV). 
Host factors needed for hantavirus entry remain largely enigmatic and therapeutics are 
unavailable. To identify cellular requirements for ANDV infection, we performed two 
parallel genetic screens. Analysis of a large library of insertionally mutagenized human 
haploid cells and a siRNA genomic screen converged on components (SREBP-2, SCAP, 
S1P and S2P) of the sterol regulatory pathway as critically important for infection by 
ANDV. The significance of this pathway was confirmed using functionally deficient cells, 
TALEN-mediated gene disruption, RNA interference and pharmacologic inhibition. 
Disruption of sterol regulatory complex function impaired ANDV internalization without 
affecting virus binding. Pharmacologic manipulation of cholesterol levels demonstrated 
that ANDV entry is sensitive to changes in cellular cholesterol and raises the possibility 
that clinically approved regulators of sterol synthesis may prove useful for combating 
ANDV infection.  
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Section 3.2 – Introduction 
 
Hantaviruses are a genera of the Bunyaviridae family that includes a large 
number of human pathogens. Hantaviruses found in the Americas, the so called New 
World hantaviruses, including Andes virus (ANDV) from Argentina and Chile, can cause 
a lethal hemorrhagic fever known as hantavirus pulmonary syndrome (HPS) while the 
Old World hantaviruses from Europe and Asia are associated with Hemorrhagic Fever 
with Renal Syndrome (HFRS) (1-5). Unlike other members of the Bunyaviridae family, 
ANDV and the other hantaviruses are not transmitted by arthropod vectors but instead 
infect humans directly by aerosolized excreta from infected rodents. Entry into host cells 
by the membrane enveloped hantaviruses depends upon the viral glycoproteins GN and 
GC, which form a heterodimeric complex on the virion surface following cleavage of a 
polyprotein precursor (6-8). Although it is clear that hantaviral infection relies upon transit 
to an acidic intracellular compartment where the viral glycoproteins mediate membrane 
fusion (9,10), the overall entry process is not fully elucidated.  
As with other viruses, ANDV must utilize host cell molecules and pathways 
during the virus life cycle for replication to occur. However relatively little is known about 
how ANDV, or other hantaviruses, interact with their host cells. High-throughput genetic 
screens have changed the way viral host cofactors are identified since these approaches 
have the ability to reveal not only host cell molecules that directly interact with viral 
components to facilitate virus infection, but also the cellular pathways that orchestrate 
the expression and activity of these molecules. Identifying pathways rather than 
individual molecules that are needed for virus replication could lead to the development 
of multiple therapeutic targets. Moreover, pathways used in common by multiple viruses 
within a family would represent ideal candidates for therapeutic development.  
80 
	  
To identify cellular factors and pathways important for hantavirus replication, we 
employed two genetic screens: a haploid human cell line that was insertionally 
mutagenized with a gene-trap vector and a large-scale siRNA screen. A recombinant 
vesicular stomatitis virus (VSV) recombinant in which the ANDV glycoproteins are 
expressed on a VSV core (rVSV-ANDV (11)) focused our screening efforts on cellular 
processes involved in early steps of the ANDV infectious pathway. Key findings were 
confirmed with replication competent, wild-type ANDV. These independent genetic 
screens identified members of the major cellular cholesterol regulatory pathway as 
important for ANDV entry. Inhibiting this pathway using complementary genetic and 
pharmacologic approaches demonstrated that ANDV is exquisitely sensitive to the 
cellular levels of cholesterol. Decreased cellular cholesterol blocked ANDV infection at 
the level of virus entry. Despite normal binding to the cell surface, virus failed to be 
internalized, resulting in a profound block to infection. Overall these studies provide a 
framework with which to identify additional cellular components involved in the entry of 
ANDV, and potentially other hantaviruses, and raise the possibility that approved 
inhibitors of sterol regulation and synthesis may find clinical application in treating ANDV 
infection.  
 
Section 3.3 – Results 
 
Independent genetic screens identify members of the cholesterol regulatory 
complex as required for the entry of recombinant ANDV  
As one approach to identify human genes required for ANDV entry we employed 
an insertional mutagenesis strategy (Fig 3-1B) in the human haploid cell line (HAP1) 
(12). Approximately one billion HAP1 cells were transduced with a gene-trapping vector, 
LentiET (Lentiviral Exon Trap, Fig 3-1A), to generate a library of cells with insertionally-  
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Fig 3-1: A forward genetic screen in human haploid cells identifies MBTPS1, 
MBTPS2, SCAP, and SREBF2 as required for ANDV infection. (A) pLentiET gene-
trap vector schematic. pLentiET is diagramed 3’ to 5’, self-inactivating (SIN) 3’LTR, 
splice acceptor site (SA), internal ribosome entry site (IRES), eGFP, polyadenylation 
signal (pA), tk promoter (tk), G418 resistance gene (Neo), splice donor site (SD), mRNA 
destabilization element, 5’ LTR. Upon a successful gene-trapping event, eGFP is spiced 
into the coding transcript downstream of the native promoter. A second transcript 
encoding G418 is simultaneously produced. (B) Genetic screen strategy. 75x106 human 
haploid (HAP1) cells were mutagenized using a gene-trap vector (pLentiET) delivered 
through transduction. Cells were expanded for several passages and infected with either 
rVSV-ANDV or rVSV virus to select for cells resistant to infection. Resistant cells were 
used for gene-trap integration site analysis (total chromosomal DNA from all resistant 
cells), integrations aligned to the human genome, and integration frequency ranked. (C) 
MBTPS1 (Site 1 Protease, S1P), MBTPS2 (Site 2 Protease, S2P), SCAP (Sterol 
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Regulatory Element Binding Protein Cleavage Activating Protein), and SREBF2 (Sterol 
Regulatory Element Binding Protein 2, SREBP-2) were found to have the highest total 
number of independent integration events. Genes are depicted 5’ to 3’ with horizontal 
bars denoting exons. Sequenced integration sites are demarked based on the 
orientation of the gene-trap vector relative to the human genome (red dots: sense 
strand, blue dots: antisense stand). Significance values were calculated using the 1-
sided Fisher’s Exact test based on the unselected control library are indicated above 
each gene.  
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inactivated genes. Survival of parental and mutagenized HAP1 cells was selected for in 
parallel with either replication competent recombinant Vesicular Stomatitis Virus that 
uses its endogenous glycoprotein (rVSV-G) or a replication competent VSV enveloped 
with the glycoprotein of ANDV (rVSV-ANDV). Challenge of ~75 million LentiET 
mutagenized HAP1 cells with rVSV-ANDV produced hundreds of colonies while parental 
HAP1 cells yielded no surviving colonies when infected with rVSV-G or rVSV-ANDV. In 
contrast to the results with rVSV-ANDV, no mutagenized HAP1 cells survived selection 
with rVSV-G. Since the mutagenized cells specifically survived rVSV-ANDV infection, 
the infection resistance maps to the ANDV glycoprotein and not to the replication of the 
VSV core.  
Mutagenized HAP1 cells surviving rVSV-ANDV selection were pooled and an 
aliquot was tested for sensitivity to rVSV-ANDV and rVSV-G infection. Confirming the 
results of the screen, the selected population displayed significant resistance to rVSV-
ANDV infection while remaining sensitive to rVSV-G (Fig S3-1). Genomic DNA prepared 
from pooled rVSV-ANDV-resistant cells was used to map pLentiET genetic integration 
sites. In total, 676 independent integrations sites were mapped in the human genome 
with 80% being intragenic. Of these insertions, 253 (37%) were located within four genes 
of a sterol regulatory element-binding protein pathway: Sterol Regulatory Element 
Binding Protein 2 (SREBF2; 59 insertions), Sterol Regulatory Element Binding Protein 
Cleavage Activating Protein (SCAP; 62 insertions), Site 1 Protease (S1P; 62 insertions), 
and Site 2 Protease (S2P; 70 insertions), (Fig 3-1C). These insertional frequencies were 
compared to the insertional frequency within the HAP1 library pre-virus selection. As the 
p-values indicate (Fig 3-1C, all less than 1x10-60), it is highly unlikely for these genes to 
have been enriched by chance. Furthermore, no other genes contained more than 2 
integrations within the selected population (Table S3.1). In addition, integrations within 
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SCAP and S1P highly favor the orientation where the gene trap vector effectively 
‘‘captures’’ the transcript whereas the opposite is true for the SREBF2 gene (Fig 3-1C, 
Table S3.1).  
In parallel an RNAi screen was performed using an optimized high throughput 
luciferase-based assay in a human HEK293T cell line engineered to constitutively 
express Firefly Luciferase (ffLuc). The Ambion Druggable Genome library (9,102 genes) 
was employed in a 384-well format with 4 siRNAs per gene and 2 siRNAs per well. 
Infection was assessed using a non-replicating ANDV (VSV-(ANDV)) viral pseudotype 
system in which the native glycoprotein (VSV-(G)) was replaced with a Renilla 
Luciferase (rLuc) reporter and the ANDV glycoprotein was provided in trans (13). This 
assay exhibited a linear correlation between rLuc activity and the amount of input virus 
across a 4-log titration (data not shown). Likewise, the ffLuc signal derived from the 
HEK293T cell line correlated with cell number across a broad range and so could be 
used to assess cell viability in each well (Fig S3-2). The library was reverse-transfected 
into the HEK293T-ffLuc cells and 72 hours post-transfection cells were infected with 
VSV-(ANDV). Twenty-four hours post-infection, relative light units (RLU) for cell viability 
(firefly) and infection (Renilla) were measured. For each plate, robust Z scores were 
calculated for both cell viability and infection. Genes were identified as hits with a robust 
Z score for infection of < -1.5 in both siRNA pools (p<0.009). This stringent approach 
requires that at least 2 unique siRNAs against the gene of interest impacted infection. 
siRNAs were considered cytotoxic and excluded if they had a robust Z score for viability 
< -2 in both pools. Based on these criteria, 105 genes were identified as important for 
infection.  
To validate the genes identified in the RNAi screen and to differentiate genes 
important for ANDV glycoprotein-mediated entry from those related to replication of the  
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Table 3-1: List of candidate genes identified during siRNA screen. List of validated 
genes identified in the siRNA screen. Shown are averaged robust z-scores for the 
primary and secondary screens. Genes were identified in the primary screen as having a 
robust z-score for infection < -1.5 in both wells; robust z-score < -2 for cell viability in 
both wells was criteria for exclusion. Genes validated in the secondary screen with 
robust z-score < -1.3 for infection normalized to cell viability in duplicate wells in ≥2 
biological replicates for ANDV, but not for VSV. 	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VSV core, 3 additional, unique siRNAs targeting 96 of the initial hits were screened 
using both ANDV and VSV-(G) viral pseudotypes. Genes validated if at least one 
additional siRNA inhibited infection in at least two biological replicates of the secondary 
screen, using a cut-off of a robust Z score for infection of < -1.3 (p<0.05) with no 
cytotoxicity (robust Z score > -2). Thirty-three genes met these criteria, with 9 specific for 
ANDV glycoprotein-mediated entry (Table 3-1). Comparison of these results with the 
haploid cell screen revealed that SREBF2 was the only gene in common, making this a 
strong candidate since it influenced infection in two different screens.  
SREBP-2, SCAP, S1P, and S2P are required for entry of rVSV-ANDV  
The results obtained from the siRNA and haploid screens indicated that 
components of the sterol regulatory pathway (SREBF2, SCAP, S1P, and S2P) were 
required for rVSV-ANDV infection. To probe the importance of this pathway for 
recombinant ANDV infection, a panel of well-characterized Chinese Hamster Ovary 
(CHO) cell lines individually null for S1P, S2P, or SCAP (Fig S3-3) (14-16) were 
challenged with VSV pseudotypes bearing the VSV or ANDV glycoproteins (Fig 3-2A). 
Additionally, these cell lines were infected with VSV pseudotypes carrying the 
glycoproteins from an Old World hantavirus, Hantaan virus (HTNV). rVSV-ANDV 
infection was severely impaired showing a 1–2 log decrease in each of the mutant CHO 
cell lines, whereas the infection level by viral pseudotypes bearing the VSV G 
glycoprotein was similar to the parental CHO cells. Infection with VSV-(HTNV) 
decreased by roughly 1-log in cells null for S1P and SCAP, but not S2P, suggesting a 
more modest dependence on this pathway. A stable cell line lacking SREBF2 was not 
available, therefore SREBP-2 expression was knocked-down with two independent 
siRNAs in HEK293T cells (Fig 3-2B). Knockdown of SREBP-2 expression resulted in a 
significant (p<0.05) decrease in VSV-(ANDV) infection with no significant impact on  
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Fig 3-2: The sterol regulatory complex promotes infection of ANDV. (A) Infection of 
Chinese Hamster Ovary (CHO) cells null for S1P, S2P, or SCAP (Fig S3-3). CHO cells 
were infected with VSV-(G), rVSV-ANDV or rVSV-HTNV for 10 hours. Infections were 
quantified via flow cytometry and normalized relative to wild-type (CHO-K1) cells. Mean 
± SEM shown for three independent experiments; ***p<0.001. (Raw infection percentage 
(CHO-K1): VSV-(G)=21%, rVSV-ANDV=15%, VSV-(HTNV)=8%) (B) siRNAs directed 
against SREBF2 efficiently knock down protein expression as measured by immunoblot 
to SREBP-2 with GAPDH as a loading control. (C) HEK293T cells depleted of SREBF2 
were infected with non-replicating VSV pseudotypes bearing the indicated glycoproteins 
encoding red fluorescent protein (RFP) and infection was quantified 10hpi. Infectivity 
was normalized relative to control cells. Mean ± SEM shown for three independent 
experiments; *p<0.05. (Raw infection percentage (control): VSV- (G) = 4%, VSV-(ANDV) 
= 19%, VSV-(HTNV) = 3%) (D) TALENs were used to genetically disrupt SCAP in 
HEK293T cells. These insertions were enriched upon challenge with rVSV-ANDV and 
were all killed by VSV-G. Enrichment was measured by a non-homologous end joining 
(NHEJ) endonuclease assay where a single band (top asterisk) indicates the presence 
of wild-type sequence and the lower molecular weight doublet (lower 2 asterisks) 
represents the disrupted alleles. Densitometry was used to quantify the levels of the 
undisrupted and disrupted alleles, which is shown below.  
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VSV-G or VSV-(HTNV) infection (Fig 3-2C).  
To explore the importance of the cholesterol regulatory complex for ANDV 
glycoprotein-dependent infection in human cells we developed a Transcription Activator 
Like Exonuclease (TALEN) pair that disrupted the coding region of SCAP (TALENSCAP). 
HEK293T cells transfected with TALENSCAP were expanded and infected with rVSV-
ANDV to kill susceptible cells (Fig 3-2D). SCAP disruption was quantified pre- and post-
infection using a quantitative PCR heteroduplex cleavage assay (17). The heteroduplex 
assay revealed that following TALENSCAP transfection, ~3% of the population had 
evidence of gene disruption. After infection with rVSV-ANDV, the SCAP-disrupted 
population increased to ~43%. Sequence analysis confirmed the gene disruption (Fig 
S3-4). Enrichment for the disrupted SCAP gene was not observed in cells passaged 
without virus infection (Fig 3-2D). Wild-type VSV efficiently infected and killed the SCAP 
disrupted cells (data not shown). Taken together, these three independent experimental 
approaches provide strong genetic evidence that members of this sterol regulatory 
complex are required for efficient ANDV glycoprotein-mediated infection in diverse cell 
types and hosts.  
Cholesterol pathway inhibitors block Andes virus glycoprotein-mediated 
infectivity  
PF-429242 is a reversible, competitive inhibitor of S1P that blocks cleavage and 
subsequent of SREBP-2 and has been shown to reduce the rates of cholesterol 
synthesis in cultured cells and in mice (18). Human airway epithelia derived A549 cells 
were pretreated with varying concentrations of PF-429242 for 24 hours to allow turnover 
of activated SREBP-2 and subsequently infected with VSV-(G), rVSV-ANDV or VSV-
(HTNV) (Fig 3-3A). As expected, treatment with PF-429242 caused a dose-dependent 
reduction in the levels of total cellular cholesterol (Fig S3-5). rVSV-ANDV infectivity also  
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Fig 3-3: PF-429242 and mevastatin 
prevent efficient infection by rVSV-
ANDV. (A) A549 cells were pretreated with 
the indicated concentrations of PF-429242 
24 hours prior to infection with VSV-(G) 
(solid line), rVSV-ANDV (dashed line) or 
VSV-(HTNV) (dotted line). Cells were 
harvested 16 hours later and viral infection 
levels were quantified via flow cytometry. 
Values are normalized to untreated infection 
levels for each virus. Mean±SEM shown for 
three independent experiments; p<0.001 for 
20µM drug concentration for both rVSV-
ANDV and VSV-(HTNV) compared to 
untreated control. (Average raw infection 
percentage (untreated): VSV-(G) = 45%, 
rVSV-ANDV = 35%, VSV- (HTNV) = 14%). 
(B) Treatment of A549 cells with the HMG-
CoA Reductase inhibitor, mevastatin, blocks 
infections with Sindbis (SINV) and ANDV 
pseudoviruses. VSV-(G),VSV-(SINV), rVSV-
ANDV or vaccinia virus was used to infect 
cells pretreated with the indicated 
concentrations of mevastatin. Infections 
were quantified using flow cytometry either 
by fluorescent protein expression or indirect 
antibody staining (rVSV-ANDV). Infectivity is 
normalized relative to untreated control 
cells. Mean ± SEM shown for three 
independent experiments; p<0.001 for 10µM 
drug concentration for rVSV-ANDV 
compared to untreated control. (Average 
raw infection percentage (untreated): VSV-
(G) = 33%, VSV-(SINV) = 16%, rVSV- 
ANDV=52%, vaccinia=30%). (C) Viral 
infectivity in the presence of 5µM mevastatin 
can be rescued with the addition of normal 
FBS and mevalonate. A549 cells were 
treated as described above with DMSO or 
5µM mevastatin with delipidated FBS or 
normal FBS (not subjected to delipidation) 
with 25µM mevalonate. Cells were infected 
with pseudoviruses (VSV-(G)or VSV-
(SINV)) or rVSV-ANDV encoding RFP and 
harvested 10hpi. Infections were quantified 
using flow cytometry. Infectivity has been 
normalized relative to untreated control cells. Mean ± SEM is shown for three 
independent experiments; ** p<0.01, ***p<0.001. (Average raw infection percentage 
(FBS+DMSO): VSV-(G) = 49%, VSV-(SINV) = 14%, rVSV-ANDV = 45%).  
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decreased in a dose-dependent manner with an approximately 50-fold reduction at  
20µM PF-429242 (dashed line). PF-429242 had an intermediate effect on the infectivity 
of VSV-(HTNV) (dotted line). In contrast, VSV-(G) infection of A549 cells is only 
modestly inhibited in the presence of PF-429242 (Fig 3-3A; continuous line) at this 
concentration (20µM), however it is increasingly abrogated at concentrations ≥40µM 
(data not shown). Inhibition of rVSV-ANDV by PF-429242 was not due to delayed viral 
entry kinetics since the vast majority of fusion had occurred within the first 3 hours in the 
presence or absence of PF-429242 (Fig S3-6).  
To address whether statins, a clinically approved class of cholesterol lowering 
drugs, could significantly reduce rVSV-ANDV infectivity, we selectively inhibited 
cholesterol synthesis with the HMG-CoA reductase inhibitor mevastatin 24 hours prior to 
infection in delipidated growth medium. Pretreatment of human A549 cells with 1.25µM 
mevastatin reduced rVSV-ANDV infectivity (>10-fold, Fig 3-3B). Controls included a 
VSV-Sindbis virus pseudotype (VSV-(SINV)) known to be sensitive to sterol levels, and 
vaccinia virus which is not affected by cellular cholesterol (19,20). VSV-(SINV) and 
rVSV-ANDV displayed a dose-dependent effect of mevastatin on infection, with rVSV-
ANDV appearing significantly (p<0.05) more sensitive than VSV-(SINV) (Fig 3-3B). 
Infection by VSV-(G) also displayed a dose-dependent decrease compared to untreated 
cells; however the magnitude of this decrease was significantly less pronounced 
compared to rVSV-ANDV (Fig 3-3B). As anticipated, infection by a cholesterol-
independent virus, vaccinia, was unaffected by mevastatin treatment (Fig 3-3B). 
Supplementation of media with mevalonate and sera reversed the inhibitory effect of 
mevastatin on rVSV-ANDV infection (Fig 3-3C). This complementation was likely the 
result of a combination of mevalonate uptake and LDL scavenging from this rich FBS, 
since it is expected that the inhibition of cholesterol synthesis would enhance expression 
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of the LDL receptor. The increase in rVSV-ANDV infection under these conditions is 
consistent with the observation that cholesterol levels in statin-treated cells grown in 
FBS supplemented with mevalonate rebound to near wild-type levels (data not shown). 
Overall, VSV-G-dependent infectivity is largely unaffected (<2-fold) by 20µM PF-429242, 
or in the loss of SCAP, S1P, or S2P, or depleted SREBP-2, yet mevastatin does appear 
to have a greater impact on VSV-(G) infectivity. This effect may be the result of LDL-R 
surface expression dynamics as this family of proteins have been shown to act as VSV-
(G) receptors (21).  
Wild-type Andes virus infection is sensitive to cholesterol depletion   
Collectively, the data presented thus far have established that the cholesterol 
regulatory pathway leading to SREBP-2 cleavage is required for infection by viruses 
bearing the ANDV glycoproteins. Because this pathway regulates a number of genes 
required for sterol biosynthesis and internalization as well as cholesterol production 
within the cell, we wished to investigate whether cellular cholesterol levels are important 
for ANDV glycoprotein mediated infection. To this end, cells were treated with methyl-β-
cyclodextrin (MβCD), which extracts sterols from membranes (22). Additionally, wild-type 
ANDV (strain 9717869) was employed for this analysis. MβCD treatment of Vero cells 
had a modest effect (2-fold) on infection mediated by VSV-(G), whereas ANDV infection 
was inhibited by more than 10-fold (Fig 3-4A). Treatment with MβCD reduced total 
cellular cholesterol levels to ~80% of untreated samples (data not shown).  
To determine if the cholesterol depleting drugs used above to effectively block 
rVSV-ANDV could also inhibit infection by wild-type ANDV, Vero E6 cells pretreated with 
PF-429242, mevastatin, or DMSO were infected with ANDV. Three days post infection, 
cells were fixed, labeled with antibodies against the ANDV nucleoprotein (ANDV-N), and 
infectivity was determined by flow cytometry (Figs 3.4B and C). Treatment with either  
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Fig 3-4: Cholesterol is required for ANDV 
infection. (A) Infection of cells depleted for 
cholesterol using MβCD. Vero E6 cells were 
pretreated with MβCD for one hour prior to 
infection. After pre-incubation cells were 
extensively washed before addition of virus at 
an MOI of 3 for 2 hours and subsequently 
overlaid with fresh media. Infections were 
harvested 72hpi (ANDV) or 16hpi (VSV-(G)), 
immunostained for viral antigen and quantified 
by flow cytometry. Values are normalized to 
infection rate of untreated cells. Mean ± SEM 
shown for three independent experiments (B) 
PF-429242 or (C) mevastatin blocks infection 
with wild-type ANDV (strain 9717869). Vero E6 
cells were pretreated with DMSO, PF-429242, 
or mevastatin at the indicated concentrations 
and 24 hours later, cells were infected with virus 
at an MOI of 3 for 2 hours and subsequently 
overlaid with fresh media. All infections and 
incubations were carried out in the presence of 
indicated concentrations of PF-429242 or 
mevastatin. 72hpi (ANDV) or 16hpi (VSV-(G)) 
cells were harvested for flow cytometry, and the 
percentage of infected cells was determined by 
expression of a fluorescent reporter gene (VSV) 
or indirect fluorescent staining of ANDV N 
(ANDV). Values are normalized to infection rate 
of DMSO treated cells. Mean ± SEM shown for 
three independent experiments; ** p<0.01, 
***p<0.001. (Average raw infection percentage 
of PF-429242 experiments (No Drug): VSV-(G) 
= 53%, ANDV = 9% and mevastatin 
experiments (No Drug): ANDV = 16%).  
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PF-429242 or mevastatin had a significant and dose-dependent effect on ANDV 
infection, decreasing the percentage of infected cells by approximately 100-fold at 40µM 
PF-429242 (Fig 3-4B) and 6-fold at 10µM mevastatin (Fig 3-4C). In contrast, treatment 
with PF-429242 diminished the infectivity of VSV-(G) with roughly a 3-fold effect at both 
20µM and 40µM concentrations (Fig 3-4B). Overall, the MβCD, PF-429242, and statin 
experiments provide strong evidence that cellular cholesterol levels dictate the 
permissivity of cells to ANDV infection.  
The activity of S1P is required for virus internalization  
To investigate the mechanism by which cells lacking a functional cholesterol 
regulatory pathway resist ANDV infection, we compared early stages of the rVSV-ANDV 
replication cycle in HAP1 cells with an insertional LentiET mutation (not shown) into the 
S1P gene (HAP1S1P) that abrogates S1P protein expression (Fig S3-7). HAP1S1P cells 
were resistant to infection by rVSV-ANDV as compared with rVSV-G (Fig 3-5A), similar 
to studies in mutant CHO cells. Next, a RT-qPCR assay was used to monitor binding 
and internalization of incoming rVSV-ANDV particles. Binding was performed at 4°C with 
equal amounts of virus added to wild-type or HAP1S1P cells. After extensive washing to 
remove unbound virus, S1P-deficient cells bound ~2-fold more rVSV-ANDV virions than 
wild-type cells (Fig 3-5B) despite the fact that infection levels were ~10-fold lower (Fig 3-
5A). As expected for surface bound virus, protease treatment decreased the PCR signal 
by more than 90% for both cell lines (Fig 3-5B; background). To measure virus uptake, 
rVSV-ANDV was bound at 4°C, then cells were transferred to 37°C for one hour to allow 
virus internalization. We chose this time point because we found that rVSV-ANDV is 
resistant to the lysosomotropic agent ammonium chloride (NH4Cl) by one hour post 
infection, indicating that acid-dependent membrane fusion has occurred by this time (Fig 
S3-8). After internalization, cells were treated with protease to remove any remaining  
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Fig 3-5: Quantitative PCR analysis of viral RNA during infection of human cells. (A) 
HAP1WT or HAP1S1P cells were infected with VSV-(G) or rVSV-ANDV for 12 hours and 
cells collected for flow cytometric analysis. Infection was normalized to infection levels in 
HAP1WT cells. Mean ± SEM is shown for five independent experiments; **p<0.01. 
(Average raw infection percentages (HAP1 WT): VSV- (G)=55%, rVSV-ANDV=71%) (B) 
Binding and internalization of rVSV-ANDV. rVSV-ANDV was bound to three sets of 
HAP1WT and HAP1S1P cells for one hour on ice. One set of cells were scraped into PBS 
and washed to measure bound virions (bound). A second set of cells were treated with 
trypsin for 10 minutes to remove externally bound virions (background). A third set of 
cells were warmed to 37°C for one hour to permit endocytosis before being treated with 
trypsin to remove any remaining external virions (internal). Cells were washed 
extensively, cell pellets and associated virions were lysed for RNA extraction and viral 
RNA (vRNA) was quantified by RT-qPCR. Viral RNA values were normalized to GAPDH 
to control for input RNA levels and plotted relative to virus bound to HAP1WT cells. Mean 
± SEM is shown for three independent experiments; ** p<0.01, ***p<0.001.  
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external virions (Fig 3-5B; internal). HAP1WT cells internalized nearly 100% of the 
measured bound virus (Fig 3-5B; compare HAP1WT bound to internal). While this 
appears remarkably efficient, there is precedent for high levels of internalization with 
other viruses, as 90% of bound influenza virions are internalized under similar conditions 
(23). In contrast, S1P-deficient cells were unable to internalize rVSV-ANDV virions (Fig 
3-5B; compare HAP1WT to HAP1S1P internal). Indeed, the amount of viral RNA inside 
these cells was comparable to the background levels of virus detected on the surface of 
cells stripped with protease prior to endocytosis (Fig 3-5B; compare HAP1S1P internal to 
HAP1WT and HAP1S1P background). Given that cells lacking S1P possess a ten-fold 
defect in both ANDV-glycoprotein mediated internalization (Fig 3-5B) and infectivity (Fig 
3-5A), we infer that this internalization defect is responsible for the resistance.  
To investigate this further, we performed confocal microscopy on Vero E6 cells 
infected with DiO-labeled viral particles (Fig 3-6). This allows us to track incoming 
particles. Furthermore, DiO will stain endocytic compartments following viral fusion so 
we can monitor binding, uptake and fusion events (24). Vero E6 cells were pretreated 
with DMSO (Fig 3-6A) or the S1P-inhibitor PF-429242 (40µM, Fig 3-6B) for 24 hours. 
Following treatment, cells were chilled to 4°C and incubated for 90 minutes with sucrose-
purified viral particles previously stained with the lipophilic dye DiO. As a control for the 
virion preparation, DiO-labeled concentrated and purified supernatant from mock-
infected cells did not produce visible puncta on cells (Fig S3-9). Following incubation, 
cells were extensively washed with cold PBS and fixed with paraformaldehyde 
immediately (‘0 min’), or following an incubation at 37°C (‘20 min’). Cellular membranes 
where counterstained with Wheat Germ Agglutinan-647 and imaged by confocal 
microscopy. In the absence of drug, both rVSV-ANDV (left) and VSV-(G) (right) samples 
displayed similar patterns of distribution—at 0 minutes puncta are found distributed  
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Fig 3-6: Detection of viral particles during cellular entry. Purified and DiO-labeled 
rVSV-ANDV (left) or VSV-(G) (right) where bound to Vero E6 cells at 4°C for 90 minutes 
pretreated for 24 hours with DMSO (A) or 40µM PF-429242 (B). Cells were 
subsequently washed with cold PBS and fixed immediately (‘0 min’), or following a 20 
minute incubation at 37°C, with paraformaldehyde. Cellular membranes where 
counterstained Wheat Germ Agglutinan-647 and imaged using confocal microscopy. 
Internalized virus is indicated with an arrowhead. Representative images from 2 
independent experiments are shown.  
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along the cellular membranes, and appear internalized with larger puncta after 20 
minutes. Although viral fusion could have occurred by 20 minutes, DiO will stain 
endocytic compartments following viral fusion [24]. In agreement with the RT-qPCR 
data, pretreatment of cells with PF-429242 appears to restrict DiO-labeled rVSV-ANDV 
to the cell periphery (Fig 3-6B, left). Uptake of labeled VSV-(G) also appears to be 
impaired (Fig 3-6B, right) and is consistent with the observed 3-fold decrease in VSV-
(G)-infectivity of these cells at 40µM PF- 429242. The results are representative of two 
independent experiments. Although not quantitative, the microscopy results in S1P 
inhibited cells, coupled with the qPCR analysis in cells carrying a genetic lesion in S1P, 
suggest that a functional cholesterol regulatory pathway is needed for effective 
internalization and subsequent infection by ANDV.  
 
Section 3.4 – Discussion 
Viral entry is a complex process often requiring orchestration of protein-protein 
interactions, cellular signaling, and cellular uptake mechanisms (25). To begin dissecting 
this process for ANDV, a haploid forward genetic screen was performed. Insertional 
mutagenesis was carried out with a gene-trap vector in human haploid cells, a method 
used previously to identify host cell molecules and pathways used by an array of viral 
and bacterial pathogens (12,26-33). This approach allows near saturation of the human 
genome, although genes required for cell viability in vitro cannot be interrogated. In the 
second method, a large-scale RNAi screen provided a complementary approach by 
producing varying degrees of gene suppression and allowing one to potentially query 
genes required for cell viability. Previously, the low level extent of overlap in genes 
discovered in various RNAi screens for the same pathogen has hampered identification 
of specific requirements (34-37). By employing both of these genetic approaches, we 
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sought to identify cellular pathways important for the early stages of ANDV infection 
comprehensively. The discovery of components of a cholesterol regulatory complex as 
an ANDV entry requirement by these two independent screens reinforces the 
significance of this finding. Moreover, the identification of more than 60 independent 
insertional mutations in each of the 4 genes of this complex attests to the strength of this 
observation.  
Interestingly, integration into the SREBF2 gene appears to be dramatically 
skewed toward the ‘‘antisense’’ orientation in which the gene trap vector would not 
efficiently disrupt gene expression. We hypothesize that these integrations likely cripple, 
but not fully inactive this gene presumably due to the poor fitness of cells completely 
deficient for SREBP-2.  
The requirement for this sterol regulatory complex in ANDV infection was verified 
by several orthogonal approaches that included analysis of cells deficient in S1P, S2P, 
or SCAP function, along with generation and study of TALEN-driven deletions in SCAP, 
and siRNAs to deplete SREBP-2. These experiments confirmed the importance of this 
pathway for ANDV infection in multiple species and cells types. In addition, tests of a 
pharmacologic inhibitor of S1P, statins and cholesterol depletion extended these findings 
to wild-type ANDV. SREBP-2 functions as an initially ER-resident, regulated transcription 
factor whose activity is controlled by interactions with SCAP and proteolysis by S1P and 
S2P. After release from the ER, transit to the Golgi, proteolysis and transport to the 
nucleus, processed SREBP-2 activates transcription via Sterol Responsive Elements 
(SREs) upstream of genes such as HMG-CoA reductase, squalene synthase and the 
low density lipoprotein receptor (LDLR) which increases cholesterol production or 
uptake. Inactivating any of the four genes that were found to be important for ANDV 
entry blocks SREBP-2 mediated gene activation resulting in lower levels of cholesterol in 
99 
	  
the absence of an exogenous source. Given the cellular location of the sterol regulatory 
pathway components in the ER and cis-Golgi, they appear unlikely to play a direct role in 
ANDV entry. However, reduced expression of one or more genes transcriptionally 
induced by SREBP-2 or altered cellular cholesterol levels could account for this 
phenotype. Pharmacologic inhibitors in conjunction with delipidated media made it 
possible to separate sterol-dependent gene induction from cellular cholesterol levels. 
When cellular cholesterol levels were reduced by inhibiting cholesterol synthesis with 
mevastatin or by treating cells with MβCD, sterol-dependent gene expression is induced. 
Despite this, ANDV infection remained suppressed by more than 10-fold, arguing that it 
is the lower levels of cellular cholesterol rather than reduced expression of SREBP-2 
target genes that is important. Also consistent with this conclusion is the finding that 
infection could be restored to cholesterol-depleted cells upon addition of exogenous 
cholesterol. Altogether, these results demonstrate that ANDV entry is particularly 
sensitive to perturbations of cellular cholesterol levels.  
Several viruses have been shown to exhibit some degree of cholesterol 
dependence for entry into cells (20,38-40). In some, the effect of cholesterol depletion is 
direct and highly specific. The clearest example is the alphavirus Semliki Forest virus 
(SFV), where a mechanistic role has been demonstrated for cholesterol in membrane 
fusion. In contrast to our findings with ANDV, cholesterol-depleted cells were unaltered 
in their ability to bind and internalize SFV, but were blocked at the downstream step of 
membrane fusion, which blocked subsequent virus replication (41,42). For other viruses, 
cholesterol depletion inhibits infection indirectly by inhibiting uptake via endocytic 
pathways. Caveolin-dependent endocytosis is especially sensitive to cholesterol levels 
and internalization of non-enveloped viruses such as SV40 is blocked when cholesterol 
is depleted (43,44). In A549 cells at the concentrations of statins we employed to block 
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ANDV entry, SV40 infection appeared unchanged (data not shown) suggesting that the 
observed effects are not due to impaired caveolin-mediated entry. Clathrin-mediated 
endocytosis, a common route of entry into cells by enveloped viruses, is also sensitive to 
cholesterol depletion using β-cyclodextrin (45). However, ANDV as well as rVSV-ANDV 
infection exhibited exquisite sensitivity to cholesterol depletion and disruption of the 
sterol regulatory pathway under conditions where VSV-(G) mediated infection, a clathrin-
dependent process, was only marginally affected. Thus it is unlikely that the mechanism 
underlying reduced ANDV infection is linked to general clathrin-mediated endocytosis. It 
is possible that a modest reduction of cholesterol levels impacts lipid raft integrity with 
concomitant effects on localization of proteins needed by ANDV or upon signaling by 
proteins that partition into these cholesterol-rich domains. For example, signaling by lipid 
raft localized DAF1 has been found to be critically important for Coxsackie virus entry 
(46). Future studies will be required to examine whether lipid rafts or raft-mediated 
signaling is important for ANDV entry.  
Underscoring the importance of cholesterol homeostasis for viral entry is the 
recent observation that cellular antiviral systems interfere with cholesterol regulation or 
trafficking (reviewed in (47)). Interferon induced transmembrane proteins (IFITMs) 
appear to exert their antiviral activity by causing the accumulation of cholesterol in late 
endosomal compartments thereby blocking infection of a wide variety of viruses that 
enter through this compartment (48). Infection by several Bunyavirdae family members, 
including ANDV, is inhibited by IFITMs (49). Two other recent studies revealed that 
interferon induced production of a sterol (oxysterol 25 hydroxycholesterol), which is 
known to be involved in cholesterol homeostasis, can block infection at the point of viral 
entry (50,51). Although likely mechanistically dissimilar, our results coupled with these 
findings, highlight the importance of cholesterol homeostasis in viral entry and suggest 
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targeting this process for the development of broadly effective antivirals.  
We found that ANDV bound equally well to wild-type and S1P-deficient cells, 
suggesting that the surface levels of the cellular factors to which ANDV glycoproteins 
bind are not dependent on the sterol regulatory pathway. Whether ANDV has an 
absolute requirement for a specific cell surface receptor is not known, though the integrin 
αvβ3 has been implicated as a binding factor in some cell types (52-55). However, αvβ3 
levels were below the limits of detection in the HAP1 cells used for the insertional 
mutagenesis screen and integrins were not identified in the HEK293-based RNAi 
screen. Additionally, surface expression levels of αvβ3 on Vero cells were not affected by 
pharmacologic treatments that blocked ANDV glycoprotein-mediated infection (data not 
shown). Taken together these observations suggest that αvβ3 integrin is not involved in 
the cholesterol-dependent phenotype observed in the diverse cells used in these 
studies. This does not preclude integrin involvement in other cell types.  
Although the current screens converged on genes regulating sterol synthesis, it 
is likely that altering the parameters of the screens by including cholesterol enriched 
media or constitutively expressing activated SREBP-2 during screening, will uncover 
additional host factors and/or pathways important for ANDV entry. Finally, the sensitivity 
of ANDV to safe, effective cholesterol-lowering drugs may suggest new treatments for 
ANDV infection and pathogenesis.  
 
Section 3.5 – Material and Methods 
Viruses 
pLentiET viral pseudotypes were prepared via co-transfection of HEK293T cells with 
pCAGGS-VSV-(G) (Addgene), pSPAX (Addgene), and pLentiET genome plasmids. Viral 
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supernatants were harvested 48 hours later. Replication competent rVSV-G and rVSV-
ANDV were previously described (11,56). VSV-(HTNV), VSV-(ANDV), VSV-(SINV) and 
VSV-(G) pseudovirions were created via co-expression of a VSV-ΔG-reporter genome 
along with a pCAGGS-viral glycoprotein expression plasmid, as previously described 
(57). Wild-type ANDV (Chilean strain 9717869) was provided by Connie Schmaljohn at 
the U.S. Army Medical Research Institute of Infectious Diseases and used under BSL-3 
conditions. A recombinant Vaccinia virus expressing GFP was previously described (58).  
Haploid cell enrichment, generation and selection of the HAP1 library  
HAP1 cells were assessed by fluorescent cytometry for ploidy by Hoechst 33342 
staining of nuclei. Haploid cells were enriched by size selection to ~80% haploid 
immediately before creation of an insertionally-mutagenized library of ~1x109 cells using 
three rounds of mutagenesis with pLentiET gene-trap virus. Virus was added such that 
~80% of cells were transduced per round of mutagenesis as determined by a lenti-GFP 
control virus made in parallel. ~75 million library cells were selected with either rVSV-G 
(MOI of 2) or rVSV-ANDV (MOI of 3–5). Cells selected for resistance to rVSV-ANDV 
were collected and pooled within 3 weeks and saved as DMSO frozen stocks or used for 
chromosomal DNA preparation. Clonal populations of HAP1 cells were achieved by 
limiting dilution.  
Integration site mapping  
Chromosomal DNA was prepared from either pools or clonal populations of ANDV 
resistant HAP1 cells. A DNA amplicon preparation protocol that specifically amplifies 
LTR-host junctions was carried out essentially as previously described (59). Amplicons 
derived from pools of ANDV resistant cells or the unselected library were subjected to 
deep sequencing analysis using either 454 or Illumina-based platforms, respectively, 
and aligned to the human genome using the University of California, Santa Cruz BLAST 
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Like Alignment Tool, BLAT (hg18, version 36.1). Enrichment of the sterol regulatory 
complex genes was calculated by comparing how often that gene was mutated in the 
screen to how often the gene carries an insertion in the control library data set. For each 
sterol regulatory complex gene a P-value was calculated using the one-sided Fisher 
exact test.  
siRNA screen  
siRNAs from the Ambion Druggable genome library representing 9,102 genes were 
spotted in 54 384-well white bottom plates in a 2x2 format such that each gene was 
targeted by 2 different pools of 2 siRNAs - 4 unique siRNAs in total. Positive and 
negative control siRNAs were plated in triplicate on each plate. Using a liquid handler 
(WellMate, Thermo Fisher) to decrease variability, 0.5µL of HiPerFect (Qiagen) in 9.5µL 
of OptiMem (Gibco) was added to each well and incubated for 15 min at room 
temperature to allow complex formation. HEK293T/ffLuc cells per well were plated to 
achieve a 40nM final siRNA concentration. 72 hours post-transfection, cells were 
infected with VSV-(ANDV)*rLuc. 24hrs post-infection, firefly and Renilla luciferase 
expression were measured. Robust z-scores were calculated for each plate using the 
median and interquartile ranges of log-transformed RLUs (60). For the secondary 
screen, 3 unique siRNAs for each gene, different from those used in the primary screen, 
were obtained from Ambion and arrayed in 96-well plates.  
Viral infection assays and inhibitor studies  
Sub-confluent cells were spin-infected (45 minutes at 1200xg, 20°C) with viral 
pseudotypes and harvested for infectivity assays 8–12hr post-infection. Infected cells 
were quantified by FACS using RFP expression or staining with antibodies against the 
matrix protein of VSV (61) followed by a secondary antibody conjugated to AF-647. At 
least 104 events, in duplicate, were counted for at least three independent experiments. 
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For PF-429242 and mevastatin studies, cells were pretreated for 24hr before infection. 
All infections and overlays were carried out in the continued presence of drug or DMSO, 
for the length of the infection. For MβCD studies, cells were pretreated for one hour and 
washed prior to infection. Cells were infected with ANDV at an MOI of 3 by adding 1 mL 
of inoculum to a 6 well dish for two hours at 37°C. Viral inoculum was removed, cells 
were overlaid with fresh media containing drug (except for MβCD assays) or DMSO 
where indicated. Cells were harvested three to four days post-infection, fixed for one 
hour in 4% formaldehyde then analyzed by flow cytometry using anti-ANDV N.  
Virus binding and internalization  
rVSV-ANDV binding was performed at 4°C in 24 well plates of HAP1 cells in IMDM 
containing a 1:8 ratio of 10% FBS to delipidated FBS. After one hour on ice, cells were 
washed with ice-cold PBS to remove unbound virus, and samples to measure bound 
virus were collected by scraping cells into PBS, followed by additional washing. Trypsin-
EDTA was used to remove surface bound virus. rVSV-ANDV internalization was 
measured by first binding and washing at 4°C then incubating samples at 37°C for one 
hour in IMDM containing delipidated media. Cells were then washed with PBS and 
treated with 0.05% trypsin and washed to remove surface bound virus. Samples were 
kept on ice after the final washing step, then processed for RNA. Primers specific to the 
VSV N segment were used for RT-qPCR. Data were analyzed using the ΔΔ-CT method 
(62) by calculating the change in gene expression normalized to that of GAPDH as a 
housekeeping gene.  
TALEN-mediated disruption of SCAP and ANDV-VSV infection  
A TALEN pair targeting exon 3 in SCAP was designed and constructed as previously 
described (63). Mutations induced by non-homologous end joining (NHEJ) following 
expression of the SCAP TALEN were measured as previously described (17). Band 
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intensities were quantified using ImageJ and utilized to estimate mutation rates as 
previously described using the formula: % gene modification = 100x(1-(1-fraction 
cleaved)1/2) (64). The T7 endonuclease assay has a range of detection from 
approximately 1% to 50% NHEJ.  
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Section 3.6 – Supplemental Figures  
 
 
 
 
 
                    
 
 
 
 
 
 
 
 
Fig S3-1: Susceptibility of rVSV-ANDV-selected population. Parental HAP1 and 
mutagenized rVSV-ANDV surviving HAP1 (rVSV-ANDVR) cells were infected with rVSV 
and rVSV-ANDV. Cells were harvested 12 hpi and infection was quantified by viral 
protein expression using flow cytometry analysis. Values presented are relative infection 
levels in rVSV-ANDVR cells compared to parental HAP1 cells.  
 
 
 
 
 
 
 
 
Figure S1: Susceptibility of rVSV-ANDV-selected population 
 
 
 
 
  
107 
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig S3-2: Validation of siRNA screen controls. Non-targeting negative control and 
positive controls targeting ffLuc, rLuc, and the endosomal proton pump member 
ATP6V06 were plated in triplicate on each plate. Cytotoxic siDeath was included as a 
control for both cell viability and infection. Values are shown as percent relative to 
negative control. Using a z-score <1.5 cutoff, >95% of controls were correctly identified 
in the primary screen.  
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Figure S1:  Validation of siRNA screen controls in primary screen.  Non-targeting 
negative Control and positive controls targeting ffLuc, rLuc, and the endosomal proton 
pump member ATP6V0C were plated in triplicate on each plate.  Cytotoxic siDeath was 
included as a control for both cell viability and infection.  Values are shown as percent 
relative to negative Control.  Using a z-score < -1.5 cutoff, >97% of controls were 
correctly identified in the primary screen. 
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Fig S3-3: Validation of S1P, S2P, and SCAP depletion in CHO mutants. Reverse 
Transcriptase PCR analysis of SREBF2, SCAP, S1P, and S2P transcripts from Chinese 
Hamster Ovary cell lines of wild type (CHO-K1), MBTPS1 (S1P), MBTPS2 (S2P), and 
SCAP mutant cell lines. Cell lines were additionally validated via Western blot analysis 
(not shown). Low levels of SCAP transcripts in the CHOSCAP cells are likely due to a 
propensity towards reversion.  
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Fig S3-4: SCAP TALEN induced mutation sequences. SCAP-TALEN induced  
mutations were identified by PCR amplification of genomic DNA from SCAP-TALEN 
treated cells pre- and post-infection with ANDV. PCR amplicons were TOPO cloned 
(Invitrogen) and sequenced using the SP6 primer. 18% (4/22) of clones sequenced prior 
to infection had mutations at the TALEN cut-site, whereas 100% (24/24) of clones 
sequenced after infection showed evidence of TALEN-induced mutations. The SCAP-
TALEN cut-site is shown in bold font. The column on the right represents number of 
bases inserted or deleted. Base insertions and substitutions are shown in red.  
 
 
 
 
 
 
SCAP, Pre-infection 18% mutated (4/22 clones)
AGTCATTCTGCCAGAAGTTCCCAGGGGACAGCAGCAGGCATCCATGCTCAGGGAGTAGGTT
AGTCATTCTGCCAGAAGTTCCCAGGG-ACAGCAGCAGGCATCCATGCTCAGGGAGTAGGTT
AGTCATTCTGCCAGAAGTTCCCAGGGGAGGACAGCAGCAGGCATCCATGCTCAGGGAGTAG
AGTCATTCTGCCAGAAGTTCCCAGGGGGACAGCAGCAGGCATCCATGCTCAGGGAGTAGGT
SCAP, Post-infection 100% mutated (24/24 clones) 
AGTCATTCTGCCAGAAGTTCCCAGGGGACAGCAGCAGGCATCCATGCTCAGGGAGTAGGTT
AGTCATTCTGCCAGAAGTTCCCAGGG-ACAGCAGCAGGCATCCATGCTCAGGGAGTAGGTT
AGTCATTCTGCCAGAAGTTCCCAGGAGA--GCAGCAGGCATCCATGCTCAGGGAGTAGGTT
AGTCATTCTGCCAGAAGTTCC----GGACAGCAGCAGGCATCCATGCTCAGGGAGTAGGTT
AGTCATTCTGCCAGAAGTTCCCAG-------CAGCAGGCATCCATGCTCAGGGAGTAGGTT
AGTCATTCTGCCAGAAGTTC--------CAGCAGCAGGCATCCATGCTCAGGGAGTAGGTT
AGTCATTCTGCCAGAAGTTCC--------AACACCTCGCTGCCCTGCTCAGGGAGTACGGT
AGTCATTCTGCCAGAAGTTCCCAG----------CAGGCATCCATGCTCAGGGAGTAGGTT
AGTCATTCTGCCAGAAGTTCCCAGG-------------CATCCATGCTCAGGGAGTAGGTT
AGTCATTCTGCCAGAAGTTCCCAG--------------CATCCATGCTCAGGGAGTAGGTT
w.t.
-1
+3
+1
w.t.
-1
-2
-4
-7
-8
-8
-10
-13
-14
SCAP-F1: 5’ - CTTGTCCTGTCTCCTGTGCAG - 3’
SCAP-R1: 5’ - CACACATCAAAAAGACGGTGAC - 3’
A.
B.
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Fig S3-5: Total cellular cholesterol in PF-429242-treated Vero E6 cells. 
Measurement of cholesterol in Vero E6 cells pretreated with PF-429242 or vehicle 
(DMSO) for 24 hours shown relative to untreated cells. Mean ± SEM shown for three 
independent experiments; p<0.03 relative to control sample with all drug doses greater 
than 1.25 µM.  
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Fig S3-6: Kinetics of viral entry in cholesterol-depleted cells. Vero E6 (A) and A549 
(B) cells were pretreated with the S1P inhibitor PF-429242 (20 µM) for 24 hours prior to 
infection. Virus was bound at 4°C via spinoculation for 30 minutes, then warmed to 37°C 
to allow entry to occur. At 3.5 hpi, ammonium chloride (NH4Cl) was added to block any 
subsequent viral fusion. Cells were fixed at 10 hpi, immunostained for VSV M 
production, and infection quantified by flow cytometry.  
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Fig S3-7: S1P expression analysis. Lysates from wild-type HAP1 cells (HAP1WT), a 
HAP1 clone containing a gene-trap integration into S1P (HAP1S1P), and 293T cells 
overexpressing S1P by transient transfection (293T cmv-S1P) were subject to western 
blot analysis.  
HA
P1
 S
1P
 
GAPDH 
S1P 
HA
P1
 W
T 
29
3T
 cm
v-S
1P
 
113 
	  
 
 
Fig S3-8: Analysis of ANDV entry kinetics. An ammonium chloride time-of-addition 
assay was used to analyze kinetics of ANDV glycoprotein mediated entry. (A) Wildtype 
HAP1 (HAP1WT) or (B) S1P null (HAP1S1P) cells were chilled on ice and infected with 
rVSV-ANDV at an MOI of 10 at 4°C to allow virus to bind. Cells were warmed quickly at 
37 to initiate a synchronous infection and 50 mM NH4Cl was added at the indicated 
times post warming. Cells were fixed at 14 hpi and stained for VSV-M to visualize 
infected cells (red, VSV-M; blue, nuclei). 
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Fig S3-9: Control for DiO labeled virion preparation. Supernatant from mock-infected 
293T cells was collected, purified, concentrated, and labeled with DiO lipophilic dye 
(DiO-488, as described in the Supplemental Information) to label any lipid-containing 
debris or microsomes. Labeled stocks where then allowed to bind to Vero E6 cells at 
4°C, incubated at the indicated times at 37°C, fixed with paraformaldehyde, stained with 
Wheat Germ Agglutinin (WGA-647), mounted and deconvolution microscopy performed. 
Representative fields are provided.  
 
 
 
  
Figure S9. Control for DiO labeled virion preparation. 
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CHAPTER 4 
SUMMARY AND FUTURE DIRECTIONS 
Summary 
Section 4.1 – SFTSV and Glucosylceramide Synthesis 
 Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging 
pathogenic bunyavirus that causes severe disease in China, South Korea, and Japan. 
The earliest cases of SFTSV were retrospectively identified in Japan occurring in 2005 
(1). Recently, a closely related phlebovirus, Heartland Virus (HRTV), was identified to 
cause severe febrile illness in the Midwestern United States (2), highlighting the 
worldwide distribution of pathogenic bunyaviruses and the need to better understand 
virus-host interactions for the development of antiviral therapeutics.  
We performed a haploid forward genetic screen using a recombinant vesicular 
stomatitis virus (rVSV) encoding the glycoproteins of SFTSV in place of its own (rVSV-
SFTSV). Mutation of the human haploid cell line, HAP1 with a lentiviral gene-trap vector 
creates a library of genetic knockouts due the presence of single copy of each gene. 
Challenge of the mutagenized HAP1 cells with rVSV-SFTSV selected for cells resistant 
to SFTSV glycoprotein-mediated entry. Sequencing of lentiviral integration sites in the 
selected and unselected control populations followed by statistical enrichment analysis 
identified ~30 putative pro-viral genes.  
The most significant hit was glucosylceramide synthase (ugcg), which initiates de 
novo glycosphingolipid biosynthesis by the addition of glucose to ceramide on 
cytoplasmic face of the cis-Golgi. Using genetic and pharmacological manipulation of 
UGCG, we validated the requirement for UGCG in SFTSV and HRTV entry. UGCG 
activity is a pre-requisite for downstream ganglioside biosynthesis, which have been 
reported to be important entry factors for a number of viruses (3-6). SFTSV entry was 
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not dependent upon ganglioside formation nor did gangliosides neutralize virus prior to 
infection, indicating that the formation of glucosylceramide itself is likely the key 
requirement for SFTSV entry.  
Mechanistic studies identified that UGCG activity was needed for a post-
internalization step of the entry process. Immunofluorescence microscopy was used to 
track incoming virus particles and virions were observed in EEA1+ early endosomes and 
TGN46+ trans-Golgi by 20 minutes in a synchronized infection. Virions were rarely seen 
co-localizing with Rab7 or LAMP1, indicating that SFTSV may utilize retrograde 
transport pathways to reach the Golgi during entry rather than trafficking through the 
more canonical late endosome/lysosomal pathway. At 40 minutes, virions in normal cells 
were observed with greater frequency in TGN46+ compartments. At the same time in 
cells treated with an inhibitor of UGCG, virus-stained foci appeared enlarged, and had 
markers of EEA1 and TGN46, although not exclusively. The enlarged virus-stained 
puncta likely reflect the accumulation of virus particles within a vesicular compartment. 
Quantitative image analysis confirmed that the volume of virus-stained puncta in inhibitor 
treated cells was indeed significantly greater than those in untreated cells at 40 minutes 
post-warming, while puncta were comparable in size at 20 minutes.    
The aberrant accumulation of virus particles may be due to (1) incomplete 
priming of the viral glycoprotein (pH and/or protease-dependent), (2) mislocalization of 
proteins or macromolecules needed for proper trafficking or fusion, or (3) an altered lipid 
composition of target membranes thus preventing fusion. Previous studies on 
glucosylceramide homeostasis and its effects on the endo-lysosomal network have 
found that UGCG inhibition causes increases in endo-lysosomal pH and cholesterol 
accumulation in lysosomes (7,8). Additionally, SFTSV entry may require proteolysis of 
the viral glycoprotein by a yet unidentified serine protease (9) or rely on a cellular 
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factor(s) that undergoes a serine protease-dependent modification. One could speculate 
that during SFTSV entry, the viral glycoprotein must undergo a pH and/or protease-
dependent conformational change before trafficking to the Golgi complex for fusion. 
When UGCG is inhibited, endosomal pH is elevated, preventing a pH-dependent 
conformational change and/or pH-sensitive proteolysis. The virus can still traffic to the 
Golgi complex, but the glycoproteins are not primed for fusion and therefore accumulate 
within vesicular compartments.  
Section 4.2 – Hantaviruses and Cholesterol 
 Hantaviruses are another bunyaviral genus containing a number of pathogenic 
viruses, including Andes virus (ANDV) and Puumala virus (PUUV). Transmission of 
hantaviruses occurs by inhalation of aerosolized rodent excreta and can cause two 
syndromes, hantavirus cardiopulmonary syndrome (HPS) or hemorrhagic fever with 
renal syndrome (HFRS), depending on the strain (10). No licensed vaccines or 
therapeutics currently exist for hantaviruses in the United States. In order to identify host 
factors that are important for hantavirus entry, a haploid forward genetic screen similar to 
the one described above was performed with a rVSV encoding the glycoproteins of 
ANDV (rVSV-ANDV). The screen identified four genes (SREBF2, SCAP, S1P, S2P) that 
together function as a sterol regulatory pathway. SREBF2 is a membrane-bound 
transcription factor that is bound to SCAP and held in the ER by INSIG when cholesterol 
levels are normal. Upon cholesterol depletion, INSIG dissociates from SCAP, allowing 
SCAP to transport SREBF2 to the Golgi where it is iteratively cleaved by site-1-protease 
(S1P) and site-2-protease (S2P) to form a soluble transcription factor. Cleaved SREBF2 
is imported into the nucleus and activates transcription of genes involves in cholesterol 
synthesis and scavenging (11,12).  
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 We validated a role for the sterol regulatory pathway using Chinese hamster 
ovary (CHO) cell lines lacking each gene, genetic manipulation, and pharmacological 
inhibitors. The downstream synthesis of cholesterol was determined to be the required 
product, as the HMG-CoA reductase inhibitor mevastatin also blocked ANDV infection. 
Additionally, bypassing of HMG-CoA reductase by the addition of mevalonate in the 
presence of drug could rescue rVSV-ANDV infection. Mechanistically, virus bound with 
similar efficiency in wild-type and S1P knockout HAP1 cells, but internalization of rVSV-
ANDV particles was reduced 10-fold. This was also observed by immunofluorescence 
microscopy of incoming virus particles. In the presence of a S1P inhibitor at 20 minutes 
post-warming, virions remained at the cell periphery while virions in untreated cells had 
migrated to perinuclear regions, indicating an internalization defect. 
 An identical screen using rVSV-ANDV was carried out independently by the 
Chandran group (13). They confirmed our identification of the same sterol regulatory 
complex as well as additional genes involved in cholesterol biosynthesis, highlighting the 
reproducibility of HAP1 screens. Their study also found that cholesterol depletion by a 
S1P inhibitor affected rVSV-ANDV internalization, but over a longer period of time (>60 
minutes) they saw internalization levels reach those in untreated cells, indicating a 
kinetic issue rather than a complete blockade (13). Further experiments identified 
cholesterol was needed in target membranes for fusion, as cholesterol depletion 
severely inhibited acid-triggered virus membrane fusion at the plasma membrane (13). 
Loading of cholesterol into the membrane prior to acid-activation restored infection levels 
to those seen in normal cells. Experiments by our lab have repeated and confirmed 
similar results with rVSV-PUUV and the need for cholesterol in target membranes for 
fusion (Dyer, Drake et al. in preparation).  
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 Since cholesterol was required in target membranes for fusion, we were curious 
if other sterol species could rescue the infection defect observed with ANDV and PUUV. 
We tested pharmacological inhibitors of enzymes required for the conversion of 
desmosterol to cholesterol and 7-dehydrocholesterol to cholesterol to see of 
desmosterol or 7-dehydrocholesterol could rescue infection (Fig 4-1). In both cases, 
infection with rVSV-ANDV and rVSV-PUUV were inhibited in a dose-dependent manner, 
indicating that conversion to cholesterol was required and upstream biosynthetic 
products could not rescue infection. In the future, more careful studies using sterol 
loading into membranes before acid-activated membrane fusion at the cell surface could 
directly reveal whether cholesterol analogs can rescue fusion. 
 In addition to ANDV and PUUV, a panel of VSV pseudotypes bearing additional 
hantavirus glycoproteins was used to test whether cholesterol is universally required for 
hantavirus entry (Fig 4-2). Indeed, the Old World hantaviruses Haantan and Dobrava 
viruses as well as the New World hantavirus Sin Nombre virus were also inhibited by 
treatment with a S1P inhibitor or mevastatin. These findings indicate that cholesterol is a 
generalized requirement for hantavirus entry.    
 
Future Directions 
Section 4.3 – SFTSV 
 From the studies described in Chapter 2, we have established a relationship 
between SFTSV entry and glucosylceramide (GlcCer) homeostasis. We have shown 
that decreased GlcCer levels result in the accumulation of virus particles within a 
vesicular compartment in the cell, consistent with a mislocalization and/or fusion defect. 
However, additional experiments would provide more insight into the functional 
consequences of GlcCer depletion during SFTSV entry.  
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 We were able to partially rescue rVSV-SFTSV infection (2.6-fold over control) 
when an siRNA-resistant UGCG plasmid was expressed in siUGCG knockdown cells. 
However, plasmid transfection was relatively inefficient (only 20% of control cells were 
GFP+) compared to siRNA transfection (>80% efficiency), and this inefficiency may 
explain why complete rescue was not achieved. Previous reports have found that 
glucosylceramide homeostasis can be restored by exogenous addition of 
glucosylsphingosine (GlcSph), which is then acylated to form glucosylceramide (7,14). 
Interestingly, addition of GlcCer to UGCG-inhibitor treated cells does not rescue 
glycosphingolipid (GSL) accumulation in lysosomes, but can be incorporated into de 
novo synthesized GSLs (7). These findings suggests that two pools of GlcCer may exist 
within a cell, one that leads to GSL biosynthesis and another that regulates endocytic 
transport (7). It will therefore be important to determine if exogenous GlcSph addition to 
siUGCG treated cells rescues rVSV-SFTSV infection. As a control, we would include 
galactosphingosine (GalSph), which cannot reconstitute cellular GlcCer and does not 
restore GSL accumulation defects (7,14).  
  Studies with UUKV and RVFV have shown that the optimal pH of fusion is 5.5 or 
below (15,16) and that virus is resistant to ammonium chloride addition by 20 minutes 
post-internalization (15,17). Similar experiments have yet to be carried out with SFTSV 
and would be useful for determining the pH threshold for viral fusion and the kinetics of 
SFTSV acid triggered events. Acid bypass or acid-triggered cell-cell fusion experiments 
would elucidate the pH threshold for SFTSV fusion and provide insight into 
compartments that SFTSV must traffic to or through during entry. If SFTSV infection 
cannot be initiated by acid-bypass at the cell surface, it would suggest that proteolysis 
and/or interaction with an intracellular receptor or factor is also necessary for entry, 
similar to the requirements for Ebola virus and Lassa virus entry as discussed in Chapter 
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1 (18-20). This may also explain the protease dependence noted by the Pohlmann lab 
(9). 
 In addition to acid-bypass experiments, advancements in live-cell imaging and 
the development of reagents that can detect membrane fusion would allow us to 
investigate the kinetics and location of SFTSV fusion. Specifically, we recently acquired 
a VSV pseudotype virus containing the P protein fused to mNeonGreen, an 
exceptionally bright fluorescent protein (21,22). VSV P protein associates with viral 
ribonucleoproteins (RNP). When virus membranes are concomitantly labeled with self-
quenching DiO, virus fusion and RNP release can be observed by the dequenching and 
diffusion of DiO and separation of mNeonGreen RNP, respectively (21). SFTSV 
glycoproteins can be pseudotyped onto this VSV core, loaded with DiO, and used for 
similar live-cell microscopy fusion kinetic studies. Additionally, we can load a non-
fluorescent rVSV-SFTSV with DiO and infect cells transfected with GFP-tagged cellular 
markers such as Rab5, Rab7, and LAMP-1. Dequenching of DiO in GFP+ compartments 
would indicate the location where hemi-fusion is occurring (21). Both of these 
experiments would be conducted in normal and UGCG-inhibited cells to compare the 
frequency, kinetics, and localization of fusion between these two conditions.    
 Our observation of rVSV-SFTSV virions within TGN46+ trans-Golgi is the first 
reported observation of a bunyavirus trafficking to the Golgi during entry. Given this 
novel observation, more careful studies investigating the trafficking of incoming particles 
need to be completed. The use of VSV-SFTSV pseudotypes carrying mNeonGreen 
RNPs will help limit our studies to genome-containing particles, which have the ability to 
be infectious. Additional time points (e.g. 30, 60 minutes) in fixed cell microscopy 
experiments will provide more resolution to the trafficking kinetics. Other cellular proteins 
should also be included as well, such as cis-Golgi GM130, ER-resident calnexin, and the 
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multi-vesciular body (MVB) marker CD63. The nairovirus Crimean-Congo hemorrhagic 
fever virus (CCHFV) has been reported to traffic to and fuse within MVBs (23), and 
MVBs have not been extensively looked at during the entry of other bunyaviruses. In 
addition to other cellular markers, other cell types should also be investigated to 
determine whether these observations were limited to A549 cells. U-2 OS and Huh7 
cells are both readily permissible to SFTSV infection and would be good candidates for 
future studies (9,24). Cell type-dependent endocytic processes have been observed for 
RVFV, as independent studies in different cell lines have reported RVFV to utilize 
clathrin-mediated endocytosis, caveolin-mediated endocytosis, and macropinocytosis, 
respectively (16,25,26). 
 We have established that UGCG is critical for the entry of SFTSV as well as the 
closely related HRTV. However, UGCG perturbation did not affect replication of the 
distantly related RVFV. Given that SFTSV and HRTV are tick-transmitted while RVFV is 
mosquito-transmitted, it would be interesting to assess whether UGCG dependency was 
restricted to the difference in transmitting vector. The sequences of phlebovirus 
glycoproteins are readily available in the NCBI database and can be used to synthesize 
codon-optimized glycoproteins for the generation of VSV core pseudotypes. 
Glycoproteins to investigate would include Sandfly fever Sicilian virus and Punta Toro 
virus from the sandfly/mosquito-transmitted viruses, tick-transmitted UUKV, and the 
newly identified tick-borne Malsoor virus and Hunter Island Group virus, which cluster 
phylogenetically with SFTSV (Fig 2-4A). UUKV virus is a BSL-2+ pathogen, therefore 
infections with authentic UUKV could be carried out easily. We have also recently 
acquired authentic HRTV (strain MO-4), and UGCG dependency can be re-evaluated in 
the context of bona fide HRTV infection, although quantification of infection is currently 
limited to plaque assays from infected supernatants. Together, these experiments would 
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determine if a requirement for UGCG is evolutionarily conserved amongst certain groups 
of phleboviruses.  
  While Chapter 2 focused on the top hit from the HAP1 screen with rVSV-SFTSV, 
several additional genes were also found to be statistically enriched within the selected 
population. In order to test whether these other genes play a role in SFTSV entry, we 
tested 52 of the most significant genes in a siRNA mini-screen. Three independent 
siRNAs per gene were arrayed in 96 well plates and reverse-transfected into 293T cells 
constitutively expressing firefly luciferase. Three days post-transfection the cells were 
infected with VSV-SFTSV or VSV pseudotypes encoding renilla luciferase. Twenty-four 
hours post-infection renilla and firefly luciferase activity was assessed to determine 
infection levels and cell viability, respectively. For each well, renilla luciferase activity 
was normalized to firefly luciferase as a surrogate for cell number, standardized relative 
to a negative control siRNA, and then averaged across four independent experiments. 
The results from the mini-screen are summarized in Fig 4-3. Genes were considered 
validated if at least 2 out of 3 siRNAs showed a ≥50% decrease in infection for rVSV-
SFTSV and differentially inhibited rVSV-SFTSV over VSV. From this approach we 
validated OCM, ROBO2, SPAG9, TTC28, and UBE2H (described in Table 4-1). 
Additional experiments will aim to characterize the role of these genes in SFTSV entry. 
  Lastly, only 4,502 integration sites were mapped in the rVSV-SFTSV selected 
population. This in turn limits the statistical power of the enrichment analysis. Since the 
selected population was first sequenced, much advancement has been made in the 
methods for DNA library preparation (Sherman, Nobles, Berry et al submitted). 
Additional sequencing of stored genomic DNA from the virus-selected population may 
uncover additional pro-viral host factors and identify other factors that may function in 
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conjunction with UGCG to provide a clearer picture of the role of glucosylceramide in 
SFTSV entry.  
Section 4.4 – Hantaviruses 
 We have established that hantavirus entry is highly sensitive to cholesterol 
depletion, more so than other viruses known to require cholesterol, such as Semliki 
Forest virus and Sindbis virus (27-29). Cholesterol appears to be required for efficient 
internalization as well as fusion of virus and host membranes. Future investigations 
could probe how cholesterol depletion affects the internalization kinetics of ANDV. While 
ANDV has been reported to utilize a clathrin and caveolin-independent endocytic 
mechanism (30), cholesterol is critical for caveolae formation and therefore depletion 
could slow caveolin-dependent endocytosis. Future investigations could more thoroughly 
assess whether caveolar uptake is important for ANDV and, more broadly, hantavirus 
entry. Additionally, ANDV and PUUV fusion have been shown to require cholesterol in 
the target membrane (13 and Dyer, Drake et al in preparation). It would be interesting to 
evaluate whether reconstitution of cholesterol-depleted cells with other cholesterol 
analogs (e.g. desmosterol, lanosterol, ketosterone) could rescue fusion and infection 
with these viruses (31). Semliki forest virus has been shown to directly engage 
cholesterol during the fusion process (32), and given the sensitivity of hantaviruses to 
cholesterol perturbation, biochemical and structural studies to evaluate direct binding of 
ANDV glycoprotein to cholesterol may provide insight into the mechanism of fusion. 
Insight into the cholesterol requirement may also be gained by selecting for mutations in 
the hantaviral glycoproteins expressed by rVSV-ANDV or rVSV-PUUV using 
pharmacological inhibitors of cholesterol synthesis or lines carrying CRISPR-generated 
knockous of S1P.  
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 Cholesterol synthesis inhibiting drugs such as mevastain are routinely used in 
human medicine to reduce total cholesterol levels. Given the availability of FDA-
approved HMG CoA-reductase inhibitors (i.e. statins) and that they inhibit ANDV and 
PUUV infection in cell culture (13,33 and Dyer, Drake et al. in preparation), these 
compounds provide an attractive potential antiviral therapeutic. It would be interesting to 
evaluate the effect of statins in an animal model of ANDV infection (34,35). Also, given 
the widespread use of statins and high annual incidence of PUUV infections in Europe 
(over 2,000 annually) retrospective epidemiological investigation of cholesterol levels, 
statin usage and PUUV infection could potentially provide insights into the risk factors 
and outcomes of cholesterol and hantaviral disease (36). However, additional factors 
such as age, pre-existing medical conditions, and lifestyle may complicate analyses.  
 
Concluding Remarks 
 Bunyaviruses are the largest RNA virus family with over 350 species identified; 
however their interactions with mammalian hosts are, in general, poorly understood. 
Haploid forward genetic screening is a powerful tool to identify host factors that are 
critical for bunyavirus infection, with particular focus on the early events of virus entry. 
Through the studies presented here, we have elucidated two key host factors, 
glucosylceramide and cholesterol, that are required for phlebovirus and hantavirus entry, 
respectively. Future investigations will seek to more clearly understand the mechanism 
by which these factors contribute to entry and evaluate additional host factors potentially 
required for these viruses. We also plan to screen additional bunyaviruses with the 
motivation to discover other novel virus-host interactions.  
  
132 
	  
         
 
 
 
Fig 4-1: Inhibitors of cholesterol biosynthesis block entry of ANDV and PUUV. 
A549 cells were pre-treated for 24 hours in DMEM (10% delipidated FBS) with various 
inhibitors of cholesterol biosynthesis prior to infection with rVSV-ANDV, rVSV-PUUV, or 
VSV. Drug was kept in the media during the course of infection. Ten hours post-
infection, cells were harvested and infection levels were assesed by immunostaining for 
VSV M expression and quantified using flow cytometry. Mean ± S.E.M. for three 
independent experiments. (A) PF-429242 – site-1-protease (S1P) inhibitor (B) 
Mevastatin – HMG-CoA reductase (HMGCR) inhibitor (C) Triparanol – Desmosterol Δ24 
reductase (DHCR24) inhibitor (D) AY-9944 – Δ7-dehydrocholesterol reductase (DHCR7) 
inhibitor 
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Fig 4-2: Cellular entry of diverse hantaviruses is inhibited by cholesterol 
depletion. A549 cells were pre-treated with the HMG-CoA reductase inhibitor 
mevastatin (A) or S1P inhibitor PF-429242 (B) for 24 hours before infection with a panel 
of RFP-expressing VSV pseudotypes bearing bunyavirus glycoproteins or VSV G (VSV). 
Drug was kept in the media throughout the infection. Twelve hours post-infection cells 
were collected and infection levels were determined by RFP expression using a flow 
cytometer. Vaccinia virus (VACV) was also included as a negative control in (A). Mean ± 
S.E.M. for three independent experiments. ANDV = Andes virus, SNV = Sin Nombre 
virus, PUUV = Puumala virus, DOBV = Dobrava virus, HTNV = Hantaan virus, RVFV = 
Rift Valley Fever Virus, LACV = LaCrosse virus.   
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Fig 4-3: siRNA mini-screen of top hits from rVSV-SFTSV HAP1 screen. Three 
independent siRNAs (labeled 1, 2, 3) per gene were arrayed in separate wells of a 96 
well plate and used to reverse-transfect 293T cells constitutively expressing firefly 
luciferase (ffLuc). Knockdown was allowed to occur for 72 hours before cells were 
infected with VSV-SFTSV or VSV pseudotypes encoding renilla luciferase (rLuc) in place 
of VSV G. Twenty-four hours post-infection cells were lysed and luciferase activity was 
measured using the Dual-Glo Luciferase Assay kit and read on a luminometer. For each 
well, rLuc values were normalized to ffLuc values to control for cell number. Infection is 
expressed normalized to a control non-targeting siRNA and the average of four 
independent experiments. Arrows indicate genes where at least 2 out of 3 siRNAs had a 
≥50% decrease in VSV-SFTSV infection. 
  
135 
	  
     Table 4-1: Genes validated in VSV-SFTSV siRNA mini-screen  
 
 
aRefSeq annotated functions, acquired from NCBI (http://www.ncbi.nlm.nih.gov/) 
bLocalization information acquired from COMPARTMENTS database (37) 
(http://compartments.jensenlab.org/) 
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